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Summary 
 
Background 
 
Since the early 1990s, Vietnam has been experiencing an HIV/AIDS epidemic with a 
general prevalence rate of 0.42 % in 2008 and a projected prevalence rate in 2012 of 
0.47%. Although the general HIV prevalence rate is considered low, the virus heavily 
affects some at-risk population groups in Vietnam, including commercial sex 
workers, injectable drug users and the men who have sex with men. According to 
studies, prevalence among these groups is considerable, up to 65%. Risky sexual 
behaviours are common practice in all three groups, and the chain of infection is 
intertwined. Besides, the situation is rendered even more complex in respect of HIV 
transmission prevention and PLHA treatment because of a governmental zero 
tolerance policy in respect of drug-users and a high level of stigma and discrimination 
towards PLHA in the Vietnamese society. 
 
In that context, the active fight against HIV in Vietnam began in earnest at the end of 
2003, with the arrival of one major international donor scheme, namely PEPFAR, 
followed in 2006 by the start of disbursement of the Global Fund, and the active work 
of the World Bank and DFID and other bilateral agencies, amounting to US$ 114 
million in the single year 2008. At the same time, the Vietnamese government was 
spending US$9.7 million on the fight against HIV amounting to less than 1% of the 
Ministry of Health’s budget. As a consequence, Vietnam became highly dependant on 
international aid to finance its fight against the epidemic. Meanwhile, it is estimated 
that about 30% of the needs are covered in terms of prevention activities and medical 
assistance to PLHA. 
 
There is thus a critical need for identifying the most cost-effective models of 
intervention in the Vietnamese context to help scale-up programmes in the country 
and meet the needs in respect of both prevention and treatment.  
 
It is in this context of limited resources and high social barriers for at-risk population 
that the French non-governmental organisation, Médecins du Monde, developed an 
integrated prevention and care model, implemented at the end of 2005 in Tay Ho, a 
district of Hanoi. The MDM has undertaken both financial and technical support and 
the main components of its model include a prevention component consisting of a 
mobile outreach team and the VCT unit, and a care and treatment department 
including adherence training, support through home-based care and HAART. 
 
The assumptions that led Médecins du Monde to implement such of model of action 
were that integrating prevention, detection, and care & treatment services within the 
same structure would help better targeting and attracting at-risk populations, hence 
increase programme performance, and finally build a cost-effective response through 
cost-savings and internal programme synergies. 
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Goal and objectives 
 
The goal of this research is to test the hypothesis on which this model of intervention 
relies: that the integration of outreach, detection and care & treatment components 
within the same outpatient clinic, in the Vietnamese context, results in a high caseload 
of at-risk clients and patients along with structural economy of scale, translating in 
high cost-effectiveness levels for the model’s key components. 
 
As such, the goal of the research translates into the following objectives: 
! Assessing model’s outputs by analysing prevention, testing and care & 
treatment components performance in term of provision, coverage, 
utilisation and impact 
! Analysing central components of the model (VCT and HAART) cost-
effectiveness, vs. the null-set scenario, and standards reflected in 
international literature 
! Analysing potential sources of synergies within the program and their 
impact on the cost-effectiveness level of its key components 
 
Method 
 
This research is based on a bottom-up three-layer analysis: 
• one related to each programme’s component performance and output; 
• another related to each programme component's costs and unit costs; and 
• a third related to the cost-effectiveness analysis of the programme's two 
central components, the VCT and the care and treatment services 
 
Results are presented as follows: 
• A first part presenting performance results 
• A second dedicated to the financial and economic analysis, laying out: 
o Model’s components financial unit-costs 
o Key components – VCT and care & treatment – cost-
effectiveness analysis, with two sub-parts, a first one on the 
analysis of synergies within the model based on financial unit-
costs analysis, and a sensitivity analysis based as well on 
financial unit-costs 
 
For each layer, the method of data collection and analysis is designed to address some 
field-related constraints including that: 
• the research is partly based on retrospective data; 
• the field is not designed to conduct academic research; and  
• the M&E system at field level is limited and cannot be adapted for the purpose 
of the research. 
 
The theoretical foundation of the thesis is founded on: 
• Habicht’s guidance on the development of programme performance indicators 
in terms of provision, coverage, utilisation and impact; 
• the World Health Organisation-CHOICE guideline on cost-effectiveness 
analysis; and 
• an adaptation of the step-down accounting methodology to allocate indirect 
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costs in a systematic fashion and ensure transferability of the results 
 
Findings 
 
The underlying hypothesises supporting the implementation of that model of 
intervention combining prevention and care & treatment components proved true.  
 
The model promoted strong synergies, which contributed to the increase in numbers 
of patients attending at the OPC level. Critical harm reduction activities could be 
carried out directly in the city’s hotspots while at the same time the mobile outreach 
team was identifying potential PLHA in need of a treatment. The concentration of 
these two functions within one team reduced the cost per client referred for VCT, and 
helped to raise awareness of existing medical services offered by the OPC targeting 
directly the most at-risk populations.  
 
The integration saved as well costs by boosting the demand for the clinic’s services 
and the use of the significant resources invested in the setting up of such a model in 
term of fixed capital and trainings. The model worked as a system with positive 
feedback loops preventing new infections and actively treating identified People 
Living with HIV/AIDS through levelling off social barriers. This system worked not 
only from outreach to treatment, but certainly as well from treatment to outreach by 
increasing VCT attraction, at-risk persons being aware of the presence of immediately 
free medical services within the same structure. 
 
As calculated in our research, the average ICR of the VCT unit vs. the null set 
scenario was 12 I$/DALY(3,0) averted, well below World Health Organisation-
CHOICE SEAR indicator of 40 I$, and 252 I$/DALY(3,0) averted for the care & 
treatment unit, well in line with international standards. A model in which outreach 
and detection services were not integrated with care and treatment service would have 
increased unit costs (by a factor of four (4)), resulting in the medical component 
running costs per DALY averted far below international standards. The same would 
have been the case had the VCT unit not been integrated with the mobile outreach 
service, at least in the first two (2) years of the programme's operation. Integrating the 
mobile outreach team with the services offered by the VCT unit, cut costs to the latter 
by a factor of three (3). Nonetheless factors related to adherence to treatment and the 
delay in identifying patients for testing and treatment hampered the global cost-
effectiveness of the programme. 
 
Conclusion 
 
The model is cost-effective, yet limited.  
First, the demonstrated synergy highly depends on the context in which the 
programme operates. Were the prevalence in the target population to decrease below 
15%, the synergy between the mobile outreach team and the VCT unit would begin to 
disappear. Moreover, were VCT services to be mainstreamed in Vietnamese society, 
the extra-cost incurred by the work of the mobile outreach team would hinder this 
synergy. Second, because of contextual limitations the model showed only an average 
cost-effectiveness by international standards, especially within its medical 
component. The model was unable to retain pre-ARV patients in sufficient numbers, 
or to convince them to abide by the OPC protocols in the absence of critical 
Summary 
 
 9 
complementary services, such as Methadone Maintenance Therapy, and/or early 
access to ART. The introduction of a Methadone Maintenance Therapy in an 
environment in which about 60% of PLHA are opiate-users would change 
dramatically the outcome of HAART, not to mention reducing HIV transmission. 
Third, in our views, the main limiting issue of this model might be the intense 
technical support it needed to be implemented and supervised. Indeed, the presence of 
an external NGO, such as MDM, though necessary in the international co-operation 
scheme, added critical costs to that programme. Over three years, the share of NGO 
expenses was considerable, amounting to 58.1% of the total. This cost share reflected 
the complexity of setting up the programme in the Vietnamese environment and the 
necessity to channel international funding, control spending, report to donors, and 
ensure the overall technical supervision of the model. Besides, costs also rose because 
the general NGOs co-operation system in Vietnam creates significant market 
distortions as a result of a limited local pool of skilled labour creating niche job 
markets. It is hence likely that the international system in place inflated costs at the 
NGO level by creating not only job-market distortions, but also several time-
consuming tasks, such as reports, proposal writing, seeking fund prolongation 
agreements, and juggling different accounting and report norms.  
 
As such, the question remains on how transfer both financial and technical burden to 
local authorities in a context of limited resources. 
The Vietnamese government spends US$1,100,000,000 on health care according to 
official figures from the National Office of Statistic, representing an expense per 
citizen of US$13.75, including general administrative costs. The sole medicine cost if 
the current number of PLHA (240,000) in Vietnam were to have access to first-line 
HAART rises to a minimum US$24,000,000 per year (or 3% of the total health 
budget), excluding medicines and management costs.  Apply the model’s average cost 
to follow-up a patient for one year of HAART, including medical management and 
biological follow-up in an optimal situation (average caseload of 750 patients), and 
that cost would exceed US$200,000,000 a year, (or almost 20% of the annual health 
budget).  This excludes integrating general supervision and management costs, which, 
depending on the efficiency of the system put in place by the Vietnamese authorities, 
could add an extra 30% to the total. 
 
It seems that in the long term, the matter of the context and technical assistance are 
central. Though cost-effective and well adapted to the current constraints of the 
Vietnamese environment, the Tay Ho OPC approach is only a short-term solution 
until prevention and detection activities are mainstreamed and social obstacles lifted 
off. It could well be the best model to address HIV/AIDS in the Vietnamese context, 
or in any other places where concentrated epidemics are evident to quickly break an 
epidemic. Yet, the issue of the social and financial sustainability of such models 
remains and should be specifically explored. As such, it appears that research in the 
future should start focusing not only on the best mix of activities, but on the best 
model of technical assistance delivery, transfer and sustainability. 
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Background: HIV in Vietnam: a concentrated epidemic 
 The patterns of the epidemic 
Since the early 1990s, Vietnam has been experiencing an HIV/AIDS epidemic (Quan 
2000, Hien 2002, Ruxrungtham, 2004) with a general prevalence rate of 0.42 % in 
2008 and a projected prevalence rate in 2012 of 0.47% (UNAIDS- 
www.unaids.org.vn). 
 
Figure 1 The projected HIV epidemic dynamic: estimated number of People Living 
with HIV/AIDS and general HIV prevalence in Vietnam from 2007 to 2010 
The HIV epidemic in Vietnam (source UNAIDS Vietnam, Ministry of Health Vietnam, 2009)
0.00%
0.10%
0.20%
0.30%
0.40%
0.50%
0.60%
0.70%
0.80%
0.90%
1.00%
150000
170000
190000
210000
230000
250000
270000
290000
Adult HIV prevalence (age 15-49) 0.41% 0.42% 0.43% 0.44% 0.47%
Estimated number of PLHIV (all
ages)
220000 231000 243000 254000 280000
⊇2007 2008 ⊇2009 ⊇2010 ⊇2012
 
Source: UNAIDS 
 
 
Although the general HIV prevalence rate is considered low, the virus heavily affects 
some at-risk population groups in Vietnam, including commercial sex workers 
(CSW), injectable drug users (IDU) and the men who have sex with men (MSM). 
According to studies, prevalence among these groups is considerable.  
 
For instance, measured prevalence for IDUs ranged from 23.9% in Hanoi (IBSS 
2006) to 32% in Long An province (Tran 2006) and 65.8% in Haiphong (IBSS 2006). 
The situation is only a little better among CSW, with differences according to the type 
of sex-work (street-based or karaoke/bar/club-based) being practised. Studies show 
prevalence ranging from 7% to18% for bar/club- and street-based CSW in Ho Chi 
Minh City (Nemoto 2008), from 9.4% to 22.6% for those in Hanoi (IBSS 2006) and 
3% to 29% in the Can Tho province (IBSS 2006). Meanwhile, the situation among the 
MSM group is alarming, with estimated prevalence ranging from 5,3% in Ho Chi 
Minh City to 9.4% in Hanoi (IBSS 2006). 
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Risky sexual behaviours are common practice in all three groups. Needle-sharing is  
common among IDUs (Tran 2006), with 15% to 47% reporting sharing needles (IBSS 
2006). Condoms are inconsistently used by commercial sex-workers. Research shows  
inconsistent  condom use associated with up to 85% of the CSWs interviewed (Tran 
2008, Nemoto 2008, Nguyen 2009), and sexually-transmitted infections reported in 
66.7% of the cases in the 12 months prior to the study (Tran 2008).  The MSM-sex-
worker sub-group appears to present the same characteristics. In one study (Clatts 
2007), 47.4% of MSM-sex workers respondents reported not using condoms when 
engaging in anal sex. 
 
As a result, sex-workers’ clients become a potential bridging population. In a recent 
study (Nguyen 2009), 55.8% of the clients interviewed were found to be potential or 
active bridger because of their inconsistent condom use and marital status, with 
consistent HSV1 & 2 infection rates (21% and 33%). 
 
The chain of infection is intertwined. Injectable-drug users may have unprotected sex 
with CSWs, and thus have high rates of sexually-transmitted infections.  A 2006 study 
reported a sexually-transmitted infection rate of 30% among IDUs (Go 2006). 
Injectable drug users may also have high-risk sex with casual partners as reported in 
Bac Ninh, where 33% of a sample of IDUs reported risky sexual behaviour 
(Schumacher 2008). Studies of CSWs, especially those street-based showed similar 
high-risk behaviours: 5.7% of the CSW in Nha Trang (Tran 2008), 17% of the CSW 
in Hanoi and Can Tho (IBSS 2006), and 30% of street-based CSW in Ho Chi Minh 
City (Nemoto 2008) reported such behaviours. 
 
It is clear that knowledge, attitudes and practice among at-risk groups need 
improvement. In the 2006 IBSS survey, a meagre 9.2% of the IDUs interviewed in 
Hanoi and Ho Chi Minh City could correctly identify ways of preventing HIV 
infection and/or reject misconceptions about HIV transmission. 
 
 Stigma and discrimination 
The situation is complex in Vietnam in respect of  CSWs, IDUs and MSM.  
In response to the rapid evolution and increase in drug use, notably heroin, in the 
country (Nguyen 2008), the Vietnamese government has been enforcing a zero 
tolerance policy in respect of drug users, and thus undermining harm-reduction efforts 
(Hammet 2007, Thanh 2009). In parallel, factors of social stigma and law 
enforcement have resulted in a grey area for commercial-sex work. Because the 
environment for CSWs is so hostile, they are fearful and driven underground and 
become “non-visible” (Johnston 2006). This combination of factors certainly makes 
harm-reduction, outreach, detection and medical work more complex because 
disclosure of HIV status in itself brings such risk. (Go 2006). 
 
Nonetheless, the situation is improving with greater acceptance from the authorities 
and the local population of peer-based harm-reduction programmes, though progress 
remains fragile (Walsh 2008, Ngo 2009). In most of the country, harm-reduction 
programmes are now authorised by local authorities, yet with some limits imposed by 
the police. Needle-exchange activities remain forbidden for the time being, and severe 
rehabilitation programmes are still enforced throughout the country (Hammet 2008). 
Clearly, the country is in a transition. 
Introduction : background, objectives of the research, material and method 
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 The fight against the HIV epidemic in Vietnam 
The active fight against HIV in Vietnam began in earnest at the end of 2003, with the 
arrival of one major international donor scheme, namely PEPFAR1, followed in 2006 
by the start of disbursement of the Global Fund, and the active work of the World 
Bank and DFID2 and other bilateral agencies listed in Figure 2. 
Figure 2 The international aid: international financial contribution to the fight 
against HIV in Vietnam from 2004 to 2008 per donors. 
International financial contribution to the fight against HIV in Vietnam 2004-2008 
(UNAIDS source, in current million USD, logarithmic scale)
0.1
1
10
100
1000
Pepfar 18 26 32 65 88.9
Global Fund 2 2.2 3
Asian Development Bank 1 0.75 0.5 2.5 6.2
UK-DFID 3.2 4.55
World Bank 3 5 6
Aus AID/Netherlands 2
Swedich International
Development Agency
0.965 0.95 0.42
Ford Foundation 0.633 0.938 0.418 0.693 1.85
Clinton Foundation 0.75 1.5 1.5
TOTAL 19.633 27.688 39.633 81.043 114.42
2004 2005 2006 2007 2008
 
Source:UNAIDS 
 
 
Thanks to this co-operation, at the end of 2007 30% of people living with HIV/AIDS 
(PLHA) in immediate need of Highly Active Anti-Retroviral Treatment (HAART) 
were receiving it (UNGASS3 3rd country report, 2006). As of September 2008, 24,500 
PLHA were receiving HAART through PEPFAR. The PEPFAR-supported prevention 
                                                
1  The Presidential Emergency Plan for AIDS Relief 
2  Department For International Development (UK) 
3  United Nations General Assembly Special Session 
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sites were active in 40 of the 64 existing Vietnamese provinces, reaching in a year a 
reported 480,600 at-risk persons  
(http://www.pepfar.gov/press/countries/profiles/116324.htm).  
 
At the same time, the Vietnamese government was spending US$9.7 million on the 
fight against HIV (UNGASS 3rd country report, 2006), amounting to less than 1% of 
the Ministry of Health’s budget. As a consequence, Vietnam became highly 
dependant on international aid to finance its fight against the epidemic. According to 
the Vietnamese Administration for HIV/AIDS Control, international aid accounted 
for 80% of national spending on HIV in 2008. This dependency to foreign aid makes 
the situation fragile with Vietnam about to achieve middle-income status in 2010. 
Because of this new economic status, Vietnam might lose a significant share of that 
international aid in a context where more than 70% of the needs are not covered and 
the latest projections do not show a decrease in the general prevalence (UNAIDS). 
Furthermore, the government's resources are limited. Notwithstanding a considerable 
push in public spending on health care in recent years, as shown in Figure 3, direct 
out-of-pocket payment for 86% of the global system cost in 2006 according to World 
Health Organisation4. 
 
Figure 3 The MoH spending: Public health expenditure in Vietnam in current billion 
of US$ from the year 2000 to 2007 
The Vietnamese Ministry of Health  spending 2000-2007 in current 
billion USD (office of the Public Statistic of Vietnam)
0
0.2
0.4
0.6
0.8
1
1.2
2000 2001 2002 2003 2004 2005 2006 2007
 
Source: Vietnamese Ministry of Health  
 
 
It is clear that without donor assistance the Vietnamese government would struggle to 
finance the expansion of existing HIV/AIDS prevention and treatment programmes. 
With about 30% of the needs covered in terms of prevention activities and medical 
assistance to PLHA and already an annual budget of about US$120 million, filling the 
gap would require as much as US$360 million, more than one-third of the Ministry of 
Health’s financial resources. 
                                                
4 http://www.who.int/countries/vnm/en/ 
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There is thus a critical need for identifying the most cost-effective models of 
intervention in the Vietnamese context to help scale-up programmes in the country 
and meet the needs in respect of both prevention and treatment. The objective here is 
to give access to care services to about 300,000 PLHA, the great majority of them 
young adults, as well as to expand prevention activities to ensure the epidemic is 
contained and does not spread to the general population. 
 
 The model developed by Médecins du Monde (MDM) in 
Vietnam 
It is in this context of limited resources and high social barriers for at-risk population 
that the French non-governmental organisation, Médecins du Monde, developed an 
integrated prevention and care model, implemented at the end of 2005 in Tay Ho, a 
district of Hanoi. With PEPFAR funding, MDM has been supporting a government-
run outpatient clinic offering comprehensive services, including prevention, harm-
reduction and HAART (see Figure 4). The MDM has undertaken both financial and 
technical support and the main components of its model include: 
! A prevention component consisting of two main elements: the mobile 
outreach team and the VCT unit. They work in parallel to reach a common 
goal: to reduce HIV transmission in at-risk populations in Hanoi. The 
prevention component includes harm-reduction and behaviour change 
communication activities, voluntary testing, spreading general information 
about the epidemic and referring PLHIV to the care and treatment unit. The 
general population of the city is not a primary target of the programme, though 
services are open to anyone. 
! A care and treatment department: The outpatient clinic offers a comprehensive 
service to registered patients, from adherence training and support to home-
based care and HAART. All services are provided free of charge, including 
routine biological and morphological tests (ultrasound, X-Ray, scanner). 
Hospitalisations for severe opportunistic infections are generally not covered 
by the programme, unless exceptional cases arise. 
 
 
The assumptions that led Médecins du Monde to implement such of model of action 
were that integrating prevention, detection, and care & treatment services within the 
same structure would help better targeting and attracting at-risk populations, hence 
increase programme performance, and finally build a cost-effective response through 
cost-savings and internal programme synergies. 
 
The Tay Ho model in itself is not original. It has already been set up in other 
countries. But such a comprehensive, all-encompassing model was rare in Vietnam at 
the time of implementation.  
 
(A more detailed description of the various sub-units of each component is provided 
in the annex section including staffing, working hours and links with Médecins du 
Monde) 
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Figure 4 The programme’s components : organic relations in between the program and the context 
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 Goal and objectives of the research 
According to research cited in previous sections, about one-third of the HIV 
prevention and medical care needs are covered in Vietnam. Though the HIV epidemic 
in Vietnam is growing slowly and affects primarily the younger population, long-term 
aid could be at odds with its development in the next decade. It is therefore critical to 
identify suitable responses and solutions to optimise resource allocation and to help 
build a sustainable and effective response to the epidemic. 
 
Hence, the goal of this research is to test the hypothesis on which this model of 
intervention relies:  
! the integration of outreach, detection and care & treatment  components within 
the same outpatient clinic, in the Vietnamese context, results in a high 
caseload of at-risk clients and patients along with structural economy of scale, 
translating in high cost-effectiveness levels for the model’s key components. 
 
 
As such, the goal of the research translates into the following objectives: 
! Assessing model’s outputs by analysing prevention, testing and care & 
treatment components performance in term of provision, coverage, 
utilisation and impact 
! Analysing central components of the model (VCT and HAART) cost-
effectiveness, vs. the null-set scenario, and standards reflected in 
international literature 
! Analysing potential sources of synergies within the program and their 
impact on the cost-effectiveness level of its key components 
 
 Material and method 
 Framework 
This research is based on a bottom-up three-layer analysis: 
• one related to each programme’s component performance and output; 
• another related to each programme component's costs and unit costs; and 
• a third related to the cost-effectiveness analysis of the programmes's two 
central components, the VCT and the care and treatment services 
 
Results are presented as follows: 
• A first part presenting performance results 
• A second dedicated to the financial and economic analysis, laying out: 
o Model’s components financial unit-costs 
o Key components – VCT and care & treament – cost-effectiveness 
analysis, with two sub-parts, a first one on the analysis of 
synergies within the model based on financial unit-costs analysis, 
and a sensitivity analysis based as well on financial unit-costs 
 
Key findings of each part are presented in a box at the beginning of each section. 
 
Programme’s output were directly computed and analysed from site’s primary data 
and Médecins du Monde M&E reports. Financial information comes from the 
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Médecins du Monde’s program accounting documentation. 
Data were processed used Excel® matrixes. 
 
For each layer, the method of data collection and analysis is designed to address some 
field-related constraints including that: 
• the research is partly based on retrospective data; 
• the field is not designed to conduct academic research; and  
• the M&E system at field level is limited and cannot be adapted for the purpose 
of the research. 
 
Meanwhile, the method had to be transparent, reproducible, and had to generate 
transferable information. Yet, ensuring the transferability of the results could be 
problematic. For instance, indirect costs at NGO level could represent a significant 
share of one cost-centre’s total cost. Yet, as demonstrated by T Adams (Adams 2006), 
overhead, management and supervision costs allocation methods can be a major 
obstacle to the transfer of results, because they often give conflicting 
recommendations. 
 
As a result, the theoretical foundation of the thesis is founded on: 
• Habicht’s guidance on the development of programme performance indicators 
in terms of provision, coverage, utilisation and impact (Habicht et al.1999); 
• the World Health Organisation-CHOICE guideline on cost-effectiveness 
analysis5; and 
• an adaptation of the step-down accounting methodology to allocate indirect 
costs in a systematic fashion. 
 
 Performance and impact analysis 
The programme performance analysis is the first layer of analysis of the research. Its 
aim is to ascertain the ability of the programme to reach its target population and 
measure programme’s outputs which would later translate in sensible unit-cost 
indicators. 
 
Taking into account Habicht et al’s recommendations (Habicht et al. 1999), we built a 
set of indicators for each component considering four categories: provision, 
utilisation, coverage and impact. This allowed us to track the performance of the 
programme at different stages.  
 
Provision indicators reflect the accessibility of a programme and its ability to 
effectively provide services. These could be, for instance, its geographic accessibility, 
the size of a target population within the catchment area, the quality of services 
offered at site level per staff training level, or behaviour. 
 
Utilisation indicators refer to the actual caseload and level of activity of a site or 
programme. They correspond to the output of the programme, but not its outcome. 
 
                                                
5 http://www.who.int/choice/en/ 
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Coverage indicators correspond to the interface ability of a programme in reaching its 
target population. These include, for the purposes of this research, at-risk persons and 
PLHA in Hanoi. 
 
Finally, impact indicators are directly related to the outcome(s) of a programme, its 
effect on a population health status, attitude, or knowledge. They measure the level of 
achievement of a programme’s goal. 
 
A minimum set of indicators of each type can inform the programme's intermediate 
processes, its outputs and outcomes. We will discuss again impact indicators in the 
cost-effectiveness analysis section of this dissertation by introducing the measurement 
of Disability Adjusted Life Years (DALY). The main indicators used in that section 
of the research are described in Table 1. 
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Table 1 Research's indicators: selected indicators in term of provision, utilisation, coverage and impact, classified per component 
Prevention activities 
Outreach – 
harm 
reduction 
Provision Hours of service; No. of districts covered by the team; Fees; services provided 
Utilisation No. of at-risk persons contacted 
Coverage No. of contacts per at-risk category (No. of Injectable-Drug Users contacted; No. of Commercial-Sex 
Workers contacted; No. of Men Having Sex with Men contacted; No. of Sexual Partners (SP) of an at-risk 
person contacted; No. of “others” contacted) with gender breakdown.  
HIV prevalence among referred VCT clients per at-risk category and gender. 
Impact Not applicable6 
VCT 
Provision Hours of service; fees 
Utilisation No. of clients 
No. of clients referred by the outreach team, with their risk category 
Coverage No. of clients per at-risk category (No. of IDUs contacted; No. of CSWs contacted; No. of MSM; No. of 
SPs of an at-risk person contacted; No. of “others” contacted) with gender breakdown.  
HIV prevalence among referred VCT clients per at-risk category and gender. 
HIV prevalence among non-referred VCT clients per at-risk category and gender 
Impact No. of PLHA diagnosed and referred 
No. of infections avoided7 
Care & Treatment activities 
                                                
6  Due to the nature of the research, it was not possible to measure the impact of that activity. Various teams from different programmes were operating 
in the same areas at the same time. Impact would have been impossible to establish 
7  Per say, it is not possible to measure directly the impact of VCT on HIV transmission. We used assumptions from the World Health Organisation 
(Hausler 2006, Sweat 2000)  that the average number of infections avoided ranged from 1 to 24 per 100 negative tests, with an average of 10. 
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Pre-HAART 
stage 
Provision Hours of service; fees 
Utilisation Average No. of patients at pre-HAART stage 
Coverage CD4 level at the time of registration; drug-use past or current 
Impact Drop-out ratio8 
HAART 
stage 
Provision Hours of service, fees; geographic origin of the patient 
Utilisation Average No. of active patients on HAART 
Coverage CD4 level at the time of treatment initiation 
Impact Mortality at +6 and +12 months after HAART initiation 
CD4 increase at +12 months 
CD4 increase of at least +100 points at +12 months9 
  
  
                                                
8  Because of the high drop-out level in the programme, mortality was not computed because of a massive information bias 
9  This is a definition used in the WHO guideline on HAART as an indicator of treatment success in the absence of viral load monitoring 
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 Financial and economic analysis: using World Health 
Organisation-CHOICE initiative guidance 
 
Another theoretical foundation of the research is a cost-effectiveness analysis 
guideline developed by the World Health Organisation (WHO). 
 
In the year 2000, the WHO launched an initiative around cost-effectiveness analysis 
in an effort to harmonise methodologies, and to mainstream cost-effectiveness 
research. This is known as the CHOICE initiative (Murray 2000, 
http://www.who.int/choice/en/). 
 
The WHO-CHOICE initiative includes cost-effectiveness ratios benchmarks, 
classified per region and type of intervention.  
 
The methodology prescribed by the CHOICE initiative is based on some key factors, 
including:  
• strict cost identification;  
• valuation and analysis methods;  
• the use of DALY10s as the final indicator for the calculation of ICER11 over 
QALY12 or HLY13;  
• the possibility of calculating ICER vs. the null-set scenario when no prior 
intervention is evaluated in a given field; and  
• the conduct of a sensitivity analysis.  
 
An additional external source of information that informs the method is the Global 
Burden of Disease report. The disability weight factors contained in the report are 
critical in calculating DALYs. 
 
Insofar as this research is concerned, the costs-related methodology is the most 
critical input from the CHOICE guideline. This methodology is summarized in Table 
2 , Table 3 and Table 4. 
 
We use the World Health Organisation-CHOICE method among many (Guiness 
2004, Walker 2001) to analyse the cost-effectiveness of the programme, because this 
method is internationally recognised and guarantees the transferability of the results to 
other sites and programmes. Production gains or losses are not to be included per 
CHOICE guideline, an essential factor in the context of Vietnam, in which the most 
important target populations in respect of HIV/AIDS are social outcasts. 
 
The DALYs calculated in that research are DALYs (3,0), with a time discount of 3% 
and no age factor. This calculation was based on the need for comparability. 
 
 
 
                                                
10  Disability Adjusted Life Years = Years of Life Lost  + Years of Life with Disability  
11  Incremental Cost Effectiveness Ratio 
12  Quality Adjusted Life Years 
13  Healthy Life Years 
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Table 2 WHO-CHOICE recommendations on costs allocation 
Cost of providing health 
interventions 
All necessary resources to make the 
intervention available should be included  
Cost of accessing health 
interventions 
Patients transport costs should be included 
 
Time costs should not be included if not 
relevant 
Production gains or losses Should not be included, or reported separately if relevant 
Health costs in extended years 
of life 
Should not be included 
Joint or overhead costs Should be integrated and includes higher levels of the organisational system 
Cost offsets or related health 
costs 
Already integrated provided interventions 
upon analysis are mutually exclusive 
Source: adapted from the World Health Organisation-CHOICE guideline 
 
 
Table 3 Costs valuation per WHO-CHOICE (with Hutton 2005) 
Economic prices Should be at the base of the analysis, using ingredient approach 
Transfer payment Excluded, granted direct administrative costs are identified 
Unit of account 
Traded 
goods 
Valued at the international price (CIF price if 
imported, COB price if exported) 
Non-traded 
goods 
Scarce labour includes market 
wage+benefits+extra 
Non-scarce labour should be valued at the 
average income from original sector 
Building is discussed below 
Transferability of costs across 
time 
CPI and GDP are recommended as the most 
suitable inflation indicators 
Transferability of costs across 
settings 
Ingredient approach is the determinant 
Purchase power parities can be used to transfer 
costs across countries 
Source: adapted from the World Health Organisation-CHOICE guideline 
 
 
Table 4 Cost analysis per WHO-CHOICE 
Discount rate and future cost Using a 3% or 6% discount rate over 10 years 
Annualisation of capital 
investment 
Use of an annuity factor A(n,r) 
Start up costs Should be annualised over a proposed 10-year period 
Capacity utilisation WHO uses a typical 80% 
Source: adapted from the World Health Organisation-CHOICE guideline 
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 The step-down accounting method 
The last piece of guidance comes from a well-known method to calculate unit costs in 
health care facilities, called step-down accounting. Step-down accounting is a simple 
and practical method widely described in methodology papers (Shepard 1998, Conteh 
2004, Drummond 2005) to calculate unit costs at facility level. The method is based 
on the definition of the final product(s), and hence the cost centres incurred. Unit 
costs are calculated by integrating all direct and indirect costs necessary to the 
production (see Table 5). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Source: adapted from Conteh and Walker 2004 
 
 
Using the ingredient method, all costs should be included, including those linked to 
the direct production of the activity measured, and the intermediate and indirect costs.  
SDCA defines three cost categories:  
! Direct costs: directly linked to the activities related to the cost centres; 
! Intermediate costs: operational support activities, such as laboratory, or the 
pharmacy of a hospital; and 
! Indirect costs: administration, transport, laundry, catering, cleaning and 
maintenance. 
 Adaptation of step-down accounting to allocate programme and 
non-governmental organisation shared indirect costs. 
Although step-down accounting is a gold standard method, its guidance remains 
incomplete in respect of indirect costs allocation, and especially when those are 
shared by different cost centres. This is often observed in an NGO-supported setting.  
 
Typically step-down accounting would allocate indirect shared costs to cost centres 
according to staff interviews, or the use of logbook (Conteh and Walker 2004) to 
track staff’s time allocation. The variation in these costing methods can lead to some 
shortcomings, especially when shared indirect costs represent a significant share of 
the total, as is often the case in NGO-supported programmes. The transferability of 
the results can be at stake (Adams 2006). Furthermore, it leaves little room for 
retrospective analysis because memory recollection can be subject to biases, and/or 
the use of logbook can be eluded or ignored. Moreover, work cycles can change over 
a given time period, especially at management level. Managerial and administrative 
time allocation can fluctuate wildly according to programme’s constraints. This is 
Table 5  The steps of Step-Down accounting 
 
Define the final product 
Define cost centres 
Identify the full cost for each input 
Assign inputs to cost centres 
Allocate all costs to final cost centres 
Compute total and unit costs for each cost centre 
Report results 
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especially important in the domain of NGO-supported programmes in which life 
cycles give way to significant staff time allocation variations.  
 
Therefore, we propose a systematic method to allocate shared indirect costs to cost 
centres: a method that we use consistently in the research to compute cost centres’ 
unit costs by allocating indirect costs at programme and NGO level.  
 
The method we call weighted-step-down accounting (WSDA) respects the bottom-up 
recursive approach of step-down accounting. It uses cost centres direct and 
intermediate costs as a rule to allocate programme’s and NGOs' shared indirect costs. 
 
 
WSDA separates the cost centre unit costs into four categories (see Figure 5):  
1.   Programme’s direct and intermediate costs: these reveal the core process costs; 
2. Level 1 programme’s indirect costs: these disclose the supervision and 
administrative costs of a transferred programme; 
3.  Level 2 programme’s indirect costs: these are the NGOs' technical assistance costs 
and they reflect the technical supervision requirements in the early phases of a 
programme; and 
4. Level 3 programme’s indirect costs: these are the NGOs' indirect costs and disclose 
the technical assistance afferent costs, and the interface role of the NGO in complex 
environments.  
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Cost  centre #1 
Programme’s 
direct and 
intermediate costs 
Cost centre #2 Cost centre #3 
Cost centre #4 
Level 1 Programme’s 
indirect costs : site 
management and admin 
Level 2 Programme’s indirect 
costs : NGO technical 
supervision 
Level 3 Programme’s indirect costs : 
NGO management and administration 
 
Programme 
level costs – 
Site level 
NGO level 
costs 
 
 
 
Source: PhD - VG 
 
 
 
 
 
Figure 5 The principle of WSDA : bottom-up approach from cost centres to general supervision 
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This allows for in-depth tracking of unit costs, information that reveals back-office 
costs of any given programme and that is useful in sustainability and affordability 
discussions.  
 
The method takes several steps, using financial costs, to define and integrate shared 
indirect costs in the cost centres’ unit costs (see Figure 6 and 7): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: PhD - VG 
 
 
1. The programmes’ cost centres direct and intermediate costs are calculated 
using the ingredient approach, which follows classic step-down accounting 
methodology. Concurrently, indirect costs are calculated using the same 
ingredient approach, whether they are shared or not. Non-governmental 
organisation’s costs are broken down into technical assistance areas and 
managerial and administration costs. 
2. Cost centres' direct and intermediate costs are individually reported to their 
respective global financial values to estimate their financial weight. This 
financial weight is the key determinant to allocate indirect costs at site level. 
3. Level 1 shared indirect costs are distributed to cost centres according to each 
cost centre's financial weight.  
 
 
 
 
 
 
 
 
 
 
Cost centre #2 
Weight - % 
Cost centre #1 
Weight - % 
 
 
Site’s indirect 
costs - $ 
Cost 
centre #1’s 
ind costs - 
$ 
Cost 
centre #2’s 
ind costs - 
$ 
 
Cost centre #2 
D & It costs  
Cost centre #1 
Cost centre #2 
Cost centre #1 
D & It costs  
Figure 6 the SDWA steps – part 1/2 
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      Source: PhD - VG 
 
 
4. The same is performed for an NGO's shared technical assistance costs with 
respect to its areas. Otherwise, NGOs' technical assistance costs are fully 
allocated to their respective cost centres. So we obtain for each cost centre its 
technical assistance cost (Level 2 indirect costs). 
5. Following the same logic, in which the financial weight of an activity acts as 
a rule to allocate its related indirect costs, the NGO's indirect costs (Level 3 
indirect costs) are allocated to costs centres according to the cost centres' 
technical assistance weight (the financial weight of each technical assistance 
area reported to the global technical assistance costs). 
6. Finally, all costs are added up to the cost centres  (See Figure 7) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: PhD - VG 
 
Cost centre #2 
Weight - % 
Cost centre #1 
Weight - % 
 
NGO 
technical  
assistance 
costs - $ 
Cost centre 
techn assist. 
costs #1 and 
weight 
Cost centre 
techn assist. 
costs #2 and 
weight 
Cost Centre 
NGO indirect 
costs #1 
Cost centre 
NGO indirect 
costs # 2 
 
NGO indirect 
costs - $ 
Figure 7 the SDWA steps - part 2/2 
Cost centre n 
D&It costs 
Cost centre n 
indirect costs 
Cost centre 
techn  ass ist 
costs n 
Cost centre 
NGO indirect 
costs n 
 
 
Unit 
cost n 
Figure 8 WSDA summary 
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Thus, the method produces unit costs with a great degree of flexibility in respect of 
the requirements of the analysis undertaken. It allows for greater understanding of the 
costs incurred in arriving at the final product(s).  
 
The example given here is simple and linear. Although it might reflect the theoretical 
situation of many NGO-supported interventions, some complications can arise in 
practice, such as: 
! a site might be the host of several interventions; or 
! an NGO might support different interventions. 
 
In such cases, the same logic must be applied, but with the definition of other cost 
centres, at site and/or programme level, linked to the other interventions to avoid 
double counting. This rule applies to cost centres intermediate and indirect costs, as 
well as costs borne by the NGOs. 
 
The method relies on an assumption: that indirect costs should follow the financial 
value of a given activity, and that all supervising resources are optimally allocated at 
programme level to avoid the waste of resources. But because of temporary 
difficulties and variations in a programme, or for reasons of mismanagement, some 
supervision resources might have to be over-allocated to less worthy components. For 
instance, a programme officer might have to spend more time on certain activities 
though they are of little financial value. Such discrepancies are not captured in the 
method we propose.  
 
Nonetheless, the methodology is useful for managers to identify those discrepancies: 
by conducting staff interviews to estimate their time allocation and compare it to what 
the method would predict as the optimum and to more easily identify gaps and/or 
problems. The comparison of the perception of the staff to the optimum allocation 
calculated using the method might also identify weaknesses in a programme's staffing 
mechanisms. 
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Table 6 Strengths and weaknesses of WSDA vs. Log book and staff interviews 
 Strengths Weaknesses 
Weigthed Step-
Down 
accounting 
! Allows retrospective 
analysis 
! Allocate indirect costs in a  
replicable and transferable 
manner 
! Does not catch actual staff 
time allocation 
! Might over-estimate the 
weight of an activity if 
high-costs items are 
incurred in that activity 
Log Book 
! Keeps track of staff actual 
time allocation 
! Highly subject to the 
quality of  log entries 
! Does not allow 
retrospective analysis 
! Results might not be 
transferable 
Staff interview 
! Keeps tracks of perceived  
staff time allocation 
 
! Might be subject to 
information bias 
! Considerable loss of 
information in case of staff 
turnover 
! Limits the depth of a 
retrospective analysis 
! Results might not be 
transferable 
 
 
Using financial unit costs to track synergies, inform the field, and prepare 
ground for cost-effectiveness analysis  
Sole economic costs allow for international comparisons and the full transferability of 
results. Yet, the use of financial unit costs in themselves provides an interesting 
perspective on project management and implementation to both the supervisor and the 
donor. Financial unit costs are sufficient in this case to look for potential synergies 
within the programme. Contextualised information does not hamper internal 
sensitivity analysis using key parameters variations.  
 
By easing and systematising the production of financial unit costs in a given 
economic context, the method permits comparisons across programmes operating 
within a given market. It opens the possibility for managerial structure comparisons in 
a given context, provided economic factors are homogenous. A wide variety of 
financial unit costs might compensate for the difficulties of transferring the results to 
other contexts, assuming the financial unit costs production is mainstreamed in the 
NGO environment. 
 
In any case, both financial and economic unit costs can be produced. The consistent 
use of the ingredient approach permits the transfer of financial costs to economic 
costs using the WHO-CHOICE guideline on cost valuation and analysis. And the 
comparison of financial and economic unit costs can be very informative. Major 
differences between them reveal some important market distortions because, for 
instance, of the scarcity of specialised labour or unusual tariffs on critical inputs. 
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Moreover, as costs are not annualised in a financial approach, the specificities of 
starting up a programme could be finally unveiled. Designing and implementing a 
programme in its early phase requires extra resources that a country, a state or an 
administration might not be able to mobilise. Economic costs are typically averaged 
and discounted over a 10-year period. Yet, simple financial analysis shows that 
implementing a new programme results in a surge in the use of resources, with 
financial unit costs decreasing as the project matures. Economic information might 
lose this dynamic aspect in the early phases of a programme through costs 
annualisation. 
 
Finally, permitting the production of financial unit costs by NGOs in a systematic 
fashion mainstreams the use of cost-effectiveness analysis. For the purposes of this 
research, HIV-related cost-effectiveness evaluations are carried out on a large scale 
(for example, Goldie 2006, Creese 2002, Cleary 2006, Hogan 2005). They intend to 
analyse large programmes, or a collection of programmes at national or regional level. 
Little data is available in respect of micro-scale programmes, especially those 
operated by NGOs.  
 
The complexity of carrying out a cost-effectiveness analysis in an NGO environment, 
the lack of guidance in terms of shared indirect costs allocation is a critical obstacle to 
the systematisation of cost-effectiveness analysis for obvious transferability reasons. 
We think the method we propose herein could be a way around this problem.  
 A by-product of the method: procedural intensity 
Capital intensity is a term often used in economics to describe the concentration of 
physical capital invested in a production process. We deem money is not the sole gap 
in international aid. Management is critical as a way to channel funds and interface 
with complex environments. The legitimacy of NGOs is built on their expertise and 
practical experience in implementing solutions. They often work under international 
funding mechanisms. Their added-value is mostly technical, and their credibility often 
determined by the manner in which they manage funds. International NGOs, common 
partners to some important bi- and multilateral-funding mechanisms such as  
PEPFAR or the Global Fund, are often perceived automatically as strong technical 
and fund managers. Yet little is known about their actual role and participation in the 
aid process.  
 
By offering a systematic method of shared-indirect costs allocation to calculate unit 
costs we think we could open a new field of investigation by measuring and revealing 
the interface role of the NGOs (Level 2 and 3 indirect costs – what we call procedural 
intensity).  
 
We believe this information is critical to increase the possibility of scaling up or 
transferring a programme to local health authorities. Furthermore, monitoring this 
procedural intensity allows comparisons across interventions and/or implementers, 
using financial unit costs in a given economic context, or economic unit costs at 
international level.  
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 Types of costs used in this research 
For this research, we use: 
• Financial unit costs to identify potential internal synergies between the 
programme’s components and to calculate key programme’s unit costs; and 
• Economic costs to conduct the cost-effectiveness analysis of VCT and care 
and treatment services. 
 
We also used financial costs to re-calculate the cost-effectiveness of the VCT and the 
care and treatment services to compare them to the results of the economic analysis. 
  
 
 Ethical concerns and clearance 
The ethical clearance of that research has been given by the Hanoi Medical University 
Public Health Department. 
No ethical concern has been raised by this research. 
 
The restitution of the information at local level took place in July 2010 during an 
UNAIDS/PEPFAR sponsored event at the Hanoi School of Public Health 
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Key findings 1 
Programme performance analysis key findings 
In the outreach component 
! Taking night shifts, the Outreach team offered a relevant provision of services 
to target populations but the MSM. 
! In term of coverage, the Outreach team managed to offer services in hotspots 
all over the city thanks to a dynamic mapping process. 
! In term of utilisation, the outreach team contacted 1485, 1455 and 2376 at-risk 
persons in year 0, 1 and 2. The most important groups reached where male 
IDUs (47.9%), female sex-workers (10.3%) and male People Living with 
HIV/AIDS (10.2%) 
! The MSM was not efficiently targeted with only 48 contacts in 3 years, 
probably because of the absence of MSM peer-educators in the team 
! In term if indirect impact, the outreach team referred 137, 507 and 601 clients 
to VCT in years 0, 1 and 2 (23.4% of the total) 
In the Voluntary Counselling & Testing component 
! In term of provision, the VCT opening hours seemed adequate to the target 
population although it was not opened at night or on week ends 
! As a fixed unit, VCT coverage was limited to clients with the financial means 
to be transported to the outpatient clinic (which could be equivalent from 
10,000 VND to 40,000 VND – US$0.75 to US$2.5) 
! In term of utilisation the VCT unit tested 1881 over 3 years (from 184 in year to 
1058 in year 2), of which 66.2% were directly referred by the Outreach team. 
The average infection rate of referred clients was 43.9%, and 35.7% for non-
referred clients 
! In term of impact, we estimate the VCT helped advert 122 infections 
In the care & treatment component 
! As the service was available for free from Mondays to Fridays, the provision 
was deemed excellent 
! As a result coverage of the unit was satisfactory with patients coming from the 
entire city 
! Utilisation of the service was robust with 739 patients who registered to the 
clinic over the course of the 3 years, of which 419 started HAART. 89% of the 
registered patients went through the VCT department in the first place 
! In term of impact, results seemed more fragile with 38.4% of HAART patients 
seeing a satisfactory increase in their CD4 level after 12 months of treatment 
Conclusion 
The model actually worked as a synergic flow from outreach to care & treatment 
activities with clients and patients belonging to the at-risk groups of populations 
with the exemption of MSM group. 
Results : programme’s outputs 
 36  
  
 Performance in the prevention component: outreach and 
Voluntary Counselling and Testing (VCT) 
As described in the previous chapter, the prevention component consists of two main 
elements: a mobile outreach team and a VCT unit. The two work in parallel to reach 
the goals of reducing HIV transmission in at-risk populations in Hanoi, and helping 
identify PLHA in need of treatment. 
 The mobile outreach team 
The performance of this team is evaluated in terms of provision, utilisation, and 
coverage. Direct impact is not assessed, however, because harm-reduction and 
prevention activities are too complex and subject to bias to be assessed in term of 
outcomes, so the actual impact of the team's prevention activities is not measurable. 
This is because other mobile outreach teams are operating concurrently in Hanoi, 
sometimes in the same neighbourhoods and targeting the same groups. Isolating the 
effect of the Tay Ho mobile outreach team might prove impossible, or at the very 
least present challenges to creating a sound statistic model to measure the incidence of 
HIV within hidden groups of population, Nevertheless, we propose to use the capacity 
of the team to convince at-risks persons to be tested as a proxy-indicator for this 
component.  
 Provision of services 
• Hours: the mobile team's hours of service appear adequate to meet the needs, 
particularly to respond to night time street-based activity. Nonetheless a large 
share of the commercial sex work takes place during the day, mostly in 
massage parlours and some karaoke bars, which were not identified as a 
critical target in the first phase of the programme, and hence couldn’t be 
addressed by the programme. As mentioned in the most recent survey (IBSS 
2006), HIV impacts more particularly street-based CSW who operate at night. 
As for IDUs, based on the experiences of the mobile outreach peer-educators 
most of their “outdoor” activity – trading and 'hanging out' – also takes place 
at night. In any case, limited provision of outreach services at night  lessens 
the impact of the outreach programme particularly among different sub-groups 
of the at-risk population, such as clients of CSWs in massage parlours, so-
called invisible CSWs and the MSM population. 
• The number of districts covered in the city ranged from three (3) at the 
beginning of the programme to twelve (12) after 24 months of operation. It is 
of course impossible to evaluate whether all hotspots of the city were being 
covered, because of the covert nature of commercial sex work. However, there 
was no geographical limitation to the mobile outreach team’s work in the city 
other than its ability to identify new hotspots and to keep track of a highly 
volatile population. 
• The team has an unlimited supply of condoms and needles. But, law 
enforcement in the city has created an extra-barrier to clean needle access. It 
has been near impossible to set up a needle-exchange programme because of 
policing activities and also because IDUs are a transient population, constantly 
on the move in efforts to avoid law enforcement officials. The result is that 
more needles are given away than are exchanged.  
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Although the provision of the outreach service to the two key target groups, IDUs and 
CSWs, appears to be adequate, the situation is less so for two other sub-groups: the 
bar/club-based CSWs and the MSM who do not engage in sex-work as described in 
the following sections. 
 Utilisation and coverage 
The mobile outreach team, by definition provides an outreach service, a service that 
seeks beneficiaries utilisation and coverage (per Habicht definition) of the service are 
somewhat confounded. In that case, clients would not reach out for the service, but 
the service would look for them. 
 
During the three (3) first years of programme implementation the mobile outreach 
team contacted 5,316 persons categorised at-risk, of whom 2,547 were male IDUs and 
878 were female CSWs (see Figure 9).  
 
Figure 9 Mobile team utilisation: number of at-risk clients contacted by the 
Outreach team over the course of the programme 
Mobile team utilisation - all categories, in number of 
individuals reached
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Source: PhD - VG 
 
 
The population of Hanoi is estimated to be about 4 million. But  no accurate estimates 
of the numbers of CSWs or IDUs in the city are available because these groups of 
people are generally marginalised and therefore their numbers are underreported.  
Taking into account Hanoi's estimated HIV prevalence rate of 0.45%% of the general 
population (hence a PLHA population of about 18,000 persons), it is safe to say that 
Results : programme’s outputs 
 38  
the mobile outreach team reaches about 0.13% of the general population, so probably 
a third of the potential target population. 
 
Table 7 and Figure 10 show that the mobile outreach team's coverage is consistent 
with the programme’s objectives. 
 
Table 7  Mobile team – coverage: distribution of at-risk clients contacted by the 
Outreach team per at-risk categories over the course of the programme 
Coverage – No. of at-risk persons contacted per risk category 
 Y0 Y1 Y2 Total 
Total 1485 1455 2376 5316 
Male 988 732 1720 3440 
IDU  793 362 1392 2547 
PLHA 141 233 168 542 
IDU/SW-MSM 7 15 39 61 
MSM 2 26 20 48 
Sexual partners 45 96 101 242 
Female 497 723 656 1876 
IDU 0 124 203 327 
PLHA 26 221 148 395 
SW 230 224 95 549 
IDU/SW 139 61 129 329 
Sexual partners 102 93 81 276 
Distribution of activity per risk category and gender 
 Y0 Y1 Y2 Total 
Male IDU 53.40% 24.88% 58.59% 47.91% 
Male PLHA 9.49% 16.01% 7.07% 10.20% 
IDU/SW-MSM 0.47% 1.03% 1.64% 1.15% 
MSM 0.13% 1.79% 0.84% 0.90% 
Male SP 3.03% 6.60% 4.25% 4.55% 
Female IDU 0.00% 8.52% 8.54% 6.15% 
Female PLHA 1.75% 15.19% 6.23% 7.43% 
Female SW 15.49% 15.40% 4.00% 10.33% 
Female IDU/SW 9.36% 4.19% 5.43% 6.19% 
Female SP 6.87% 6.39% 3.41% 5.19% 
TOTAL 100.00% 100.00% 100.00% 100.00% 
Source: PhD - VG 
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Figure 10 Mobile team utilisation : cumulative repartition of at-risk clients contacted 
by the Outreach team over the 3 first years of the programme 
Mobile team utilisation during the first 3 years of the programme
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During the first three (3) years of the programme, almost 50% of the at-risk persons 
reached were male IDUs. If we include male and female IDUs, and those IDUs 
engaging in sex-work that figure rises to almost 65%.  
 
It is the MSM target group that is largely under-represented in the outreach 
programme. This is because MSM, apart from those engaged in commercial sex-
work, do not frequent the same hotspots as other at-risk people. So the mobile 
outreach efforts among this group have been largely unsuccessful. A different 
approach is necessary to reach the MSM target group.  
 
A sensitivity analysis of different team compositions is suggested, to explore how 
much the composition of the peer-educator teams influences their ability to identify 
at-risk populations different from their own. In the case of our research, the 
composition of the reached population is quite similar to that of the mobile outreach 
team, with male IDUs over-represented. Peer-educators are hired instead of health 
professionals because they are thought to be more efficient in developing adequate 
micro-outreach strategies to target specific population groups.  
 
In this context, there are IDUs and street-based CSWs on the one hand and MSM on 
the other. And the term MSM encompasses a rather diverse and large population, so is 
in itself too vague.  Interviews with members of the mobile outreach team reveal that 
the MSM group includes a heterogeneous population of male IDUs who engage in sex 
work but don’t consider themselves as gay,  of married men who pay for sex, and also 
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a more openly gay population either paying for sex or not. Although categorising the 
different target groups is helpful in defining macro-strategies for intervention, it can 
also blind one to the realities of social structures because it misses some elementary 
differences between groups that have little in common in terms of exposure to risk 
and social behaviour. 
 
Another target group, the Sexual Partners (SP) of at-risk persons is also not 
adequately reached. The clients of commercial sex workers fall in this category. The 
design of the mobile outreach team obviously does not allow for engagement with 
CSW clients, despite the fact that the latter are active in the transmission of HIV. Peer 
education, however, is perhaps not the best way to reach this particular at-risk group. 
 
The lack of outreach to MSM and SP is further understood when one considers:   
! the lack of coverage of non street-based CSW venues; 
! the reluctance of CSW customers to be visible/contacted; 
! the different social dynamics that influence MSM;  
! the lack of MSM representation in the mobile outreach team, which results in 
weaker hotspot mapping for this particular at-risk group;  and 
! the team's primary focus on street-based activities. 
 
  
 Impact 
There is no evidence that needles and condoms are consistently used by target 
populations that received them, or that sufficient quantities of these prevention tools 
are distributed to meet the needs of at-risk persons identified in the hotspots covered 
by the team. In light of these realities it is proposed to harness the team's capacity to 
refer at-risk persons for VCT as a proxy to estimate the team's efficacy in changing 
the behaviours of at-risk persons. 
 
During the three-year period, the capacity of the team to refer clients to the VCT has 
gradually improved (see Figure 11) 
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Figure 11  Mobile team referral activity : number of at-risk persons referred to the VCT by the Outreach team over the course of the 
programme 
No. of at-risk persons referred to the VCT by the MT
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Source: PhD - VG
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The data shows a linear progression in the number of clients referred to the outpatient 
clinic’s VCT unit. The increase does not appear to be connected to the number of at-risk 
persons reached by the mobile outreach team (see Figure 12), but rather appears to be 
time-dependant. Whereas the number of persons contacted is fairly stable during the three 
(3) years, there is a constant increase in the number of clients referred by the mobile 
outreach team for VCT services. The convergence of a number of different factors could 
explain this pattern, including: 
• the improvement of team communication skills combined with limited turnover in 
staff; 
• the favourable response to VCT following mass-media communication plans by 
NGOs and public authorities  
• the generalisation of prevention activities in the city; 
• increased motivation among mobile team members; and 
• a dynamic mapping process that identified a pool of at-risk persons targeted by the 
team. 
 
 
Figure 12 Referred vs. Non-referred: comparison of the number of referred and non-
referred clients attending an HIV test at VCT level over the course of the programme 
Evolution of the No. of persons contacted vs. the No. of persons referred to Voluntary Counselling & Testing
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The ratio of the number of at-risk persons contacted to the number of VCT clients referred 
by the mobile team varied from 9.2% in Year 0 (Y0), to 34.8% in Y1, and 25.2% in Y2, 
with absolute values increasing over the three years. 
 
Concurrently, other VCT sites opened in the city and mobile outreach team members 
would provide clients with information about all active VCT centres. It is therefore 
possible that some at-risk persons reached by the mobile team decided to access services at 
a VCT centre other than the one running at the outpatient clinic.  
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In any case, the mobile outreach team was efficient in referring clients to the clinic's VCT 
site and improved its overall performance during the first three (3) years of the programme 
(see Table 8 and Figure 13). 
 
 
Source:  PhD - VG 
 
 
Figure 13 At-risk categories referred: cumulative number of referred clients over 3 
years classified in function of their risk category 
Number of at-risk clients referred by the mobile team to the Voluntary Counselling & Testing over 
3 years
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It should be noted that the information presented in Figure 12 is drawn from the records of 
the VCT unit, where clients were self-reporting risky behaviours. Logically, the risk 
pattern of the VCT clients is similar to the population’s contacted by the mobile outreach 
team. Notably, the numbers of MSM presenting for VCT is extremely low (about 1%), 
particularly when compared to IDUs (more than 50%). 
Table 8  The dynamic of referral by the Mobile team : identifying 3 phases over 
the course of the programme in function of the average number of referred 
clients to the VCT 
 Phase 1 Phase 2 Phase 3 
Time period Dec 2005- April 
2006 
May 2006 –April 
2008 
May 2008 – Sept 
2008 
Average of referral 
cases per month 11 cases  38 cases 53 cases 
No. of cases referred 
per MT member per 
month 
1.4 cases 4.7 cases 6.6 cases 
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The HIV prevalence among the referred clients in the VCT unit is discussed in the 
following section. 
 
 
 The VCT unit 
 Provision of service 
The operating hours of the VCT unit are not necessarily suited to the life-style of the 
targeted population. The VCT unit operates during business hours and therefore cannot 
accommodate persons who work or are active from late afternoon and through the night. 
However, the outpatient clinic records show that this does not present major obstacles to 
access. The fact that the unit has only one dedicated counsellor is also not as problematic 
as would be assumed. During the first three (3) years of the programme the counsellor 
conducted between two (2) and 12 consultations (on average 20 minutes each) per day. 
 
The fact that the outpatient clinic offers a care and treatment service in addition to VCT 
might well have boosted the perceived quality of the service, particularly because in many 
VCT sites in Hanoi are stand-alone and have no formal or direct connection to a medical 
programme. 
 Coverage 
The VCT unit is open to anyone and the services are free. Yet, for some poor clients 
transportation costs impact access because transport costs to and from the clinic range 
from VND10,000 to VND40,000. The staff at the clinic avoided asking clients their 
geographic origin in order to establish trust and create a “comfort zone” for the at-risk and 
vulnerable target audience. Yet, based on registration information, about 50% of the 
clients came from three districts surrounding the clinic. 
 
 Utilisation 
During a 33 month-period, the VCT site in Tay Ho tested 1,881 clients. From a meagre 
184 clients tested in its first year of implementation (nine months), a total of 1058 tested 
cases were reported in Y3, a five-fold increase. Men were slightly better represented 
among clients who used the VCT site (57%). Two at-risk categories showed a clear gender 
split: the Injected-Drug Users, with a sex-ratio of 79.9%, and the Sexual Partner to an at-
risk person with 26.2%.  
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Figure 14 The VCT activity: evolution of the number of VCT clients receiving a full VCT service over the course of the programme 
No. of Voluntary Counselling & Testing clients receiving their results
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On the whole, clients presenting at the VCT unit define themselves as belonging to an at-
risk group. Only 16.3% would declare being otherwise. 
 
The largest group attending the VCT unit is the IDUs, whose members constituted 46.9% 
of the total (54.2% when IDU/CSWs are included). They are followed by the SP of an at-
risk person group, who made up 24% of attendees during the first three (3) years. The third 
largest group was that of  “other”, specifically persons who declare that they fit into no at-
risk category. Notably, this category recorded the greatest increase in attendees during the 
three (3) years – from eight cases in Y1 to 190 in the Y3, a 24-fold increase in attendance 
and possibly a sign of the successful mainstreaming of VCT. The target group with the 
lowest recorded attendance is the MSM, which again is not surprising considering the 
level of stigma suffered by this population group and the limited success of the mobile 
team to reach it.  
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Figure 15 VCT clients typology: distribution of VCT clients in function of their at-risk group, group size and HIV infection rate, with discs on 
the graph proportional to group size and heights depending on their specific HIV infection ratio, all 3 years combined 
Cumulative distribution of all Voluntary Counselling & Testing clients per risk category and in-category 
prevalence over the 3 year period
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Thanks primarily to the work of the mobile outreach team, the VCT unit is well utilised 
and meets the objectives set for the site. 
 
 
Source:  PhD -VG 
 
The mobile team was of critical support to the efficacy and sustainability of the VCT unit. 
During the first 33 months of the programme, the mobile team was responsible for about 
66.2% of the unit's client activity. The link with the mobile team proved essential to the 
success of the unit  
 
The link between the mobile team and the VCT unit developed over three phases as set out 
in Figure 16 and Table 10. 
 
Table 10  The Mobile team - VCT link dynamic: identification of 3 phases in the Mobile 
team – VCT relation in term of at-risk clients referral 
 Phase 1 Phase 2 Phase 3 
Time period Dec 2005- 
April 2006 
May 2006 
–April 
2008 
May 2008 
– Sept 
2008 
Average of referral 
cases per month 11 cases  38 cases 53 cases 
Share of the VCT 
activity 100% 72% 50% 
No. of cases referred 
per MT member per 
month 
1.4 cases 4.7 cases 6.6 cases 
Source: PhD - VG 
 
 
 
 
Table 9  Referral in the VCT activity: share of referred clients in the VCT 
activity over the course of the programme 
 2005-2006 2006-2007 2007-2008 
Total of clients tested 184 639 1058 
Referred  number 137 507 601 
 share 74.46% 79.34% 56.81% 
Non-Referred number 47 132 457 
 share 25.54% 20.66% 43.19% 
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Figure 16 VCT in-flows: evolution over the course of the programme of the number of referred and non-referred clients attending VCT, and the 
share of referred clients in the total VCT activity 
referred and non-referred VCT clients flows
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Those 3 phases are: 
• Phase 1 (five [5] months): The VCT unit's client base is comprised entirely of those 
referred by the mobile outreach team. The number of referrals is initially quite low, 
with about 11 cases a month, or an average of 1.4 cases per peer-educator. This is 
likely due to the lack of knowledge of the service among at-risk populations. At 
this stage the mobile team is also still in its infancy and so it is not performing 
optimally. 
• Phase 2 (24 months):  While non-referred clients begin to access the VCT unit 
spontaneously, the cases referred through the work of the mobile team grows to 38 
a month (4.7 per peer-educator). The mobile outreach team receives more training 
on communication, and over time develop a better understanding of its intervention 
environment. Moreover, the service is also promoted through word-of-mouth by 
VCT clients, initiating a snowball effect.  
• Phase 3 (five (5) months): During this time non-referred clients account for 50% of 
those accessing the VCT unit. Clients referred by the mobile outreach team 
average 53 a month (6.6 cases per month per peer-educator).  
 
Clearly, the mobile team has a remarkable effect on the work of the VCT unit. It 
contributes to the “start up” of the programme and likely contributes to indirect  referrals 
from at-risk persons belonging to the same social networks. Awareness of the VCT unit is 
promoted solely by the mobile outreach team until June 2008. Thereafter the Tay Ho 
outpatient clinic is marketed by the  NGO Population Service International (PSI), but the 
trend of self-referrals has gathered steam long before this campaign. 
 
 
Table 11   Referred and non-referred clients risk categories: cumulative distribution of 
referred and non-referred VCT clients over the 3 years of the programme 
3 years Referred clients Non-referred clients Share of clients referred by the OMT Number Distribution Number Distribution 
IDUs only 683 54.9% 200 31.4% 77.3% 
SWs only 52 4.2% 30 4.7% 63.4% 
IDU/SW 93 7.5% 44 6.9% 67.9% 
MSM 15 1.2% 3 0.5% 83.3% 
SP 267 21.4% 187 29.4% 58.8% 
Others 135 10.8% 172 27.0% 44.0% 
ALL 1245 100.00% 636 100.00% 66.2% 
Source: PhD - VG 
 
The data in Table 11 shows clearly the active recruitment undertaken by the mobile 
outreach team among all at-risk groups. Only 10.8% of the referred clients declare that 
they belong to the “other” category, compared to 27% of those who are non-referred. 
Injectable drug users and CSWs constitute the target populations most referred by the 
mobile outreach team (77.3% and 63.4% respectively).  
 
The qualitative contribution of the mobile outreach team is even clearer when one 
considers the HIV prevalence statistics for each category in Table 12, Table 13 and Figure 
17. 
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Table 12  HIV infection rate in referred and non-referred clients: HIV infection rate in 
VCT clients in function of their at-risk category and their referred or non-referred status 
over the 3 years of the programme 
 Referred clients Non-referred clients Share of 
positive cases 
referred by 
the OMT  
Number of 
HIV positive 
tests 
Ratio 
Number of 
HIV positive 
tests 
Ratio 
IDUs only 317 46.4% 111 55.5% 74.1% 
SWs only 22 42.3% 9 30.0% 71.0% 
IDU/SW 56 60.2% 25 56.8% 69.1% 
MSM 13 86.7% 3 100.0% 81.3% 
SP 127 47.6% 69 36.9% 64.8% 
Others 11 8.1% 10 5.8% 52.4% 
ALL 546 43.9% 227 35.7% 70.6% 
Source:  PhD - VG 
 
Table 13  Evolution of the HIV infection rate among VCT clients: comparison of the 
HIV infection rate between referred (R) and non-referred (NR) VCT clients over the 3 
years of the programme in function of their at-risk category 
 Year 0 Year 1 Year 2 All  
R NR R NR R NR R NR 
IDUs 95.83% 100.00% 50.72% 50.00% 32.13% 48.95% 46.41% 55.50% 
SWs 100.00% 75.00% 44.00% 28.57% 15.79% 21.05% 42.31% 30.00% 
IDU/SW 100.00% 83.33% 50.00% 78.57% 55.56% 37.50% 60.22% 56.82% 
MSM 100.00% 0.00% 100.00% 100.00% 66.67% 100.00% 86.67% 100.00% 
SP 78.79% 63.64% 48.39% 57.14% 39.72% 32.26% 47.57% 36.90% 
Others 42.86% 0.00% 7.55% 10.71% 5.33% 3.48% 8.15% 5.81% 
ALL 89.78% 85.11% 46.15% 37.12% 31.45% 30.20% 43.86% 35.69% 
Source: PhD – VG 
 
 
Globally the prevalence is higher for referred-clients. Nonetheless, this pattern is not 
absolute, as is apparent in the statistics related to non-referred IDUs. 
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Figure 17 Referred vs. non-referred clients: comparison in term of group size and HIV infection rate between referred and non-referred clients 
attending VCT over the 3 years of the programme 
Prevalence and group-size of referred and non-referred clients
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Considering prevalence rates and numbers of clients it is clear that the mobile 
outreach team referred the majority (70.6%) of those tested positive for HIV at the 
clinic. 
 
Notably, the prevalence rate decreased at the same pace during the three years for 
both referred and non-referred clients. As noted previously, a combination of effective 
prevention and harm-reduction activities, and the depletion of an initial pool of highly 
at-risk persons are the likely explanation for this phenomenon. 
 Impact 
In a paper Hausler (2006)  cites the WHO's validation of the findings of a research 
study conducted in Kenya to assess the impact of a VCT programme, combined with 
TB and ProTEST initiatives (Sweat 2000). It was found that for 100 clients who 
tested negative, between 1 to 24 infections could be averted, with an estimated 
average of 10. 
 
If we apply that rationale to the Tay Ho site, with 21, 356 and 731 clients tested 
negative respectively in Y0, Y1 and Y2, the VCT unit helped avert 2, 36 and 74 
infections in the corresponding years (with a minimum of 0, 4 and 7 and a maximum 
of 5, 85 and 175 infections respectively). 
 
We will refer to these figures later in the cost-effectiveness analysis section dedicated 
to VCT. 
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 The Care and treatment component 
The OPC offered a comprehensive service to registered patients, from adherence 
training and support and Home-Based Care to HAART. All services were provided 
free of charge to patients including routine biological tests, and morphological tests 
(ultrasound, X-Ray, scanner) alike. The programme did not deal with cases of severe 
opportunistic infections that required hospitalisation, unless exceptional cases arose. 
 
 Performance 
The four units of the programme: he pharmacy, the laboratory, the Home-Based Care 
unit and the medical team worked in synergy and for the purposes of this study have 
been evaluated as an integrated component.  
 
 Provision 
The care and treatment service opened in the second quarter of Year 0. 
 
The service was accessible to any patient living in Hanoi inner city. All services were 
provided free of charge, but not anonymously. On registration, patients had to 
disclose their identity and proof of residence in the city. This last regulation was 
enforced with some flexibility to accommodate some migrant workers and/or patients 
with no official residence in Hanoi (residency is tightly regulated in the country, in 
order to administer access to public services). 
 
The care and treatment unit was accessible during office hours. No direct service was 
provided after 5pm or at weekends... A hotline was available to deal with emergencies 
and to ensure a continuum of service on public holidays.  
 
For the first 12 months, the programme was initially dedicated in three (3) inner-city 
districts (Tay Ho, Hoan Kiem and Ba Dinh). Thereafter, the cover area of the 
programme was extended to the 12 districts of the city. Surrounding provinces were 
not covered by the programme because this would have stretched the HBC team 
beyond capacity, though some exceptions were made on a case by case basis by the 
OPC management team. 
 Coverage 
Here we propose a map locating the patients’ district of origin to be compared to the 
initial target population of the programme. As shown in figure 18, though the 
programme was initially designed to cover only 3 districts, the majority of the patients 
were residents of other districts of Hanoi 
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Figure 18 Patients geographic origin: distribution over the 3 years of the 
programme of the registered patients in function of their district of residence, with the 
average distance from district to the outpatient clinic 
Geographic distribution of the residence of the new ARV patients per district
 (with the mean distance to Outpatient Clinic)
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Tay Ho (2.5 km) 28.30% 30.77% 13.92% 20.95%
Hoan Kiem (3 Km) 9.43% 6.15% 14.35% 11.19%
Ba Dinh (3.5 Km) 15.09% 11.54% 15.61% 14.29%
Dong Da (4.5 Km) 11.32% 15.38% 10.13% 11.90%
Hai Ba Trung (5.5 Km) 9.43% 8.46% 11.39% 10.24%
Cau Giay (6 Km) 1.89% 5.38% 2.95% 3.57%
Long Bien (6 Km) 3.77% 3.85% 11.81% 8.33%
Thanh Xuan (7 Km) 0.00% 3.85% 2.95% 2.86%
Hoang MAI (10 Km) 7.55% 4.62% 4.64% 5.00%
Tu Liem (10 Km) 1.89% 3.85% 2.53% 2.86%
Ha Dong (12 Km) 0.00% 0.00% 0.84% 0.48%
Dong Anh (14 Km) 3.77% 0.77% 2.95% 2.38%
Gia Lam (15 Km) 7.55% 5.38% 3.38% 4.52%
Thanh Tri (15 Km) 0.00% 0.00% 1.27% 0.71%
Thuong Tin (26 Km) 0.00% 0.00% 0.42% 0.24%
Bac Ninh (34 Km) 0.00% 0.00% 0.42% 0.24%
Hung Yen (34 Km) 0.00% 0.00% 0.42% 0.24%
Withing a 6 Km radius 79.25% 81.54% 80.17% 80.48%
3 first districts 52.83% 48.46% 43.88% 46.43%
Y0 Y1 Y2 3Y
 
Source: PhD - VG 
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Most patients resided near to the Outpatient Clinic. Just over 44% of the patients 
registered at the clinic resided in the three (3) districts initially targeted by the 
programme. That percentage rose to almost 77% when patients from the next three 
most immediate districts (Dong Da, Hai Ba Trung and Long Bien) were included. 
 
Proximity to the clinic appears to have been an important factor in the patients' 
decision to access services. Patients on average travelled 30 minutes on motorbike 
(main mode of transport in Hanoi) to reach the clinic, though some travelled up to an 
hour. For those travelling more than an hour to reach the clinic, anonymity was stated 
as the main factor in their decision to access services at this site. 
 
 Utilisation 
 General 
Figure 19  Medical caseload: evolution of the number of patients registering and 
registered in the outpatient clinic over the course of the programme 
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Source: PhD - VG 
 
Over the course of the programme, there was a constant increase in the number of 
patients registering at the Outpatient Clinic. In total, 739 registered at the clinic and 
had a first medical examination and staging of their infection. Not until 12 months 
into the programme did we see a significant number of patients registering each 
quarter (less than 20 per month in the first quarter of Y0). Considering the estimated 
HIV prevalence among the general population in Hanoi of 0.45%, these initial 
registration figures are quite low. They translate to a pool of PLHA in need of 
medical supervision of about 18,000. 
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Figure 20 Registering patients' biological stage: number of registering patients to 
the outpatient clinic in function of their initial CD4 count, with 4 categories of CD4 
count: [0;50], [51;100], [101;200], [>200], with CD4 count expressed in number of 
cells per mm3 
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Source: PhD -VG 
 
The data in Figure 20 and 21 provides a more detailed understanding of the “stage 
category” of the patients registered at the clinic. It is clear that patients presenting in a 
very advanced stage (CD4<100/mm3) of the disease constituted a consequent share of 
flow of patients.  
 
 
Almost 56% of the patients registering at the clinic had already developed severe 
immune depression, with a CD4 count lower than 200 cells/mm3. This could be the 
result of limited accessibility of the general HIV/AIDS services in the city, limited 
awareness among target populations of the existing and available services, and 
possibly the fear among a largely young and drug dependent population to deal with 
the disease. This is certainly another argument for the use of a mobile outreach team 
to identify and refer people for treatment before they reach a serious stage of illness, 
as well as to raise awareness at community level of existing services.  Mobile 
outreach certainly had a dramatic effect on the general medical outcomes of the 
programmes as related to mortality, as we will see later on in this section. 
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Figure 21 biological stage at registration: distribution of registering patients to the 
outpatient clinic over the course of the progamme in function of their initial CD4 
count with 4 categories of CD4 count: [0;50], [51;100], [101;200], [>200], with 
CD4 count expressed in number of cells per mm3 
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Source: PhD - VG 
 Highly Active Anti-Retroviral Treatment 
Figure 22 New HAART patients: number of newly started Highly Active Anti-
Retroviral Treatment patients over the course of the progamme 
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Source: PhD - VG 
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Not surprisingly, the number of patients starting up Highly Active Anti-Retroviral 
Treatment followed a similar trend as shown in Figure 21. In total, the OP clinic 
initiated 419 patients on Highly Active Anti-Retroviral Treatment during the three-
year period, 56% of those during the last year. The ARV treatment component of the 
programme was largely “fed” by the work of the mobile team and the VCT unit 
(about 80% of the case load).  Individuals with CD4 counts below 50 constituted 
25.8% of the total, and patients below 100 CD4/mm3, 51.6%, during the three-year 
period. 
 
 Impact 
 Intermediate impact  
The long-term objective of the Highly Active Anti-Retroviral Treatment is to increase 
CD4 counts, prevent opportunistic infections and finally add life-years to patients. 
Yet, part of the design of that the OPC programme was to ensure the follow-up of the 
patients, who were more often than not social outcasts dealing with major 
uncertainties in their lives. A Home-Based Care team and a separate adherence unit 
were added to the medical core of the unit, as a way to improve the global adherence 
of the patients not only to the treatment, but also to the various protocols in place. 
 Keeping pre-Anti-Retroviral patients active in the programme 
A major obstacle was to retain the so-called pre-ARV patients in the programme and 
have them adhere to the protocol of the OPC. Here we will look specifically at the 
ability of the centre to achieve this objective.  
 
The Tay Ho Outpatient Clinic had limited resources to keep track of patients with 
limited medical issues. Most of the extra activities, such as the work of the HBC and 
adherence teams, were dedicated to the patients on ARVs. The initial medical staging 
of the patient and the six-monthly medical check-up (biological and clinical), were 
aimed at involving the patient in the process.  
As is clear from the data in Figure 23, however, success in this regard was limited.  
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Figure 23 Pre-ARV patients LTF: number of lost-to-follow up pre-Anti-Retroviral 
patients over the course of the programme per initial CD4 count, with 4 categories of 
CD4 count: [0;50], [51;100], [101;200], [>200], with CD4 count expressed in 
number of cells per mm3 
No. of lost patients at the Pre-ARV stage in function of their CD4 count at the time of 
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Source: PhD - VG 
 
Patients with initially “high” CD4 counts (Above 200 cells/mm3) were the most 
prone to leave the programme, whereas patients with borderline or low counts (below 
200 cells/mm3) were likely to stay the course of treatment.  
 
During the three years of programme operation, the LFT (lost-to-follow-up) ratio 
followed a remarkable trend according to the initial level of CD4 of the patients, as 
shown in Figure 24. 
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Figure 24 LTF in pre-ARV patients: proportion of patients lost-to-follow up in each 
CD4 category, with 4 categories of CD4 count: [0;50], [51;100], [101;200], [>200], 
with CD4 count expressed in number of cells per mm3 
Drop-out ratio for pre-Anti-Retroviral patients over 3 years per initial 
per initial CD4 category 
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Source: PhD - VG 
 
The determinant here appears to be the access to HAART, and most likely the early 
access to such treatment. A majority of patients who were not immediately eligible 
for HAART did not return their scheduled regular check-ups, thus missing the chance 
to start ARV treatment at a stage of the disease when their health status was still 
reasonably good (see Figure 25).  
Figure 25 LTF in high-CD4 pre-ARV patients: number of patients with initial CD4 
level above 200 cells per mm3 lost-to-follow up over the course of the programme 
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As a result the programme lost, at least temporarily about 52.4% of its patients with 
high CD4 counts. This loss was serious in terms of the medical impact because most 
of those patients would often only present again when they had developed severe 
opportunistic infections. 
 
This raises questions about the value of limiting access to HAART to patients with 
low CD4 counts (under 200 cells/mm3), because the benefits of this approach might 
well be offset by the additional costs generated by returning patients with more severe 
conditions, and possibly a higher morbidity and mortality risk. 
 
 
Keeping Anti-Retroviral Treatment patient active in the programme  
The drop-out of patients was also a problem within the Highly Active Anti-Retroviral 
treatment component of the programme. 
 
 
 
Figure 26 LTF in HAART patients at +6months: lost-to-follow up ratio in each CD4 
category after 6 months of HAART over the course of the programme, with 4 
categories of CD4 count: category 1= [0;50], category 2 = [51;100], category 3 
=[101;200], category 4 = [>200], with CD4 count expressed in number of cells per 
mm3 
Drop-out ratio at +6 months of Highly Active Anti-Retroviral 
Treatment, per initial CD4 category
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Within the first six months of HAART, an average of 7.2% of patients dropped out, 
primarily patients who recorded relatively high CD4 counts at the onset of the 
treatment. It is difficult to explain that result. It is possible that the combination of the 
side-effects of the therapy combined with increased confidence might have 
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encouraged patients to discontinue treatment. The threat of an imminently serious 
condition would likely motivate patients to overcome barriers to HAART. 
 
 
Figure 27 LTF in HAART patients at +12months: lost-to-follow up ratio in each 
CD4 category after 12 months of HAART over the course of the programme, with 4 
categories of CD4 count: category 1= [0;50], category 2 = [51;100], category 3 
=[101;200], category 4 = [>200], with CD4 count expressed in number of cells per 
mm3 
Drop-out ratio within the first 12 months of Highly Active Anti-
Retroviral Treatment, per initial CD4 category
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Source: PhD - VG 
  
After 12 months of treatment, the average drop-out ratio increased only marginally 
from 7.2% to 8.59%, and the global pattern remained the same, with “high” CD4 
count patients more prone to leave the programme than those with more threatening 
levels. The first six months of treatment were critical and it was during this time that 
the majority of drop-outs (62.8%) occurred. 
 
In total, the general drop-out ratio (any patients stopping treatment for non-medical 
reasons) reaches 11% of the total initiated patients.  
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Table 14 LTF in HAART patients analysis: lost-to-follow up ratio in some selected 
patients categories, over the 3 years of the programme 
 
 
 
No. of starting up 
patients 
Dropped-out patients Patients with initial CD4>200 
Number Ratio Starting number 
Dropped-
out ratio 
Injected-Drug Users 291 35 12% 25 20% (n=5) 
Non-naïve patients 83 8 9.6% 21 23.8% (n=5) 
Male 309 32 10.3% 28 7.1% (n=2) 
Female 110 13 11.8% 10 40% (n=4) 
Initial CD4 count 100 - 200 165 21 12.7%   
Initial CD4 count > 200 38 6 15.8%   
Total of starting up patients 419 46 11% 38 15.8% (n=6) 
Source: PhD -VG 
  
 Improving the health status of the Anti-Retroviral Treatment 
patients 
 CD4 impact at +6 months 
Six months after the initiation of HAART, 41.5% of the patients, regardless of their 
initial CD4 status, had a net increase in their CD4 count, with an average of 128 
points and a median of 90. Yet, the results are heterogeneous with a standard 
deviation of 150 points (see Figure 28 and Figure 29).  
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Figure 28 CD4 increase at +6 months: net increase in active Highly Active Anti-Retroviral Treatment patients 6 months after the onset of 
treatment per initial CD4 level, with CD4 count in number of cells per mm3 
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Source: PhD – VG 
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Figure 29 Minimum increase of +50 CD4: ratio of patients in each initial CD4 category with a net increase of 50 cells per mm3 6 months after 
the onset of treatment, with 4 categories of CD4 count: category 1= [0;50], category 2 = [51;100], category 3 =[101;200], category 4 = 
[>200], with CD4 count expressed in number of cells per mm3 
Ratio of patients with at least a 50 CD4 increase after 6 months 
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 CD4 impact at +12 months 
 
Figure 30 CD4 increase at + 12 months: net increase in active Highly Active Anti-
Retroviral Treatment patients 12 months after the onset of treatment per initial CD4 
level, with CD4 count in number of cells per mm3 
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Source: PhD - VG 
 
 
Twelve months after the initiation of HAART, 49% of the patients recorded a net 
increase in their CD4 counts, with an average of 172.5 points, a median of 141, and 
standard deviation of 112 points (see Figure 30 and Figure 31). 
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Figure 31  Minimal CD4 increase of +100: ratio of patients for each initial CD4 category with a net increase of 100 cells per mm3 12 months 
after the onset of treatment, with 4 categories of CD4 count: category 1= [0;50], category 2 = [51;100], category 3 =[101;200], category 4 = 
[>200], with CD4 count expressed in number of cells per mm3 
Ratio of patients with at least a 100 CD4 increase after 12 
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Source: PhD-VG 
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About 38% of the initiated patients would record a significant increase in their CD4 
count (+100) after a full year of treatment (see Figure 31). Another 15% would 
succumb to AIDS, 8.5% would drop out, and almost 45% would not record a 
significant increase in their CD4 counts. 
 
 
Figure 32 Mortality at +6 months: mortality in Highly Active Anti-Retroviral 
Treatment patients within the first 6 months of treatment over the course of the 
programme 
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Mortality figures within the first 6 months are quite high, averaging 13.6%.  This 
period of treatment is likened to a “red zone” because as many as 81.4% of all the 
deaths recorded in the programme, occurred in this time period. 
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Figure 33 Mortality and initial CD4 count at + 6 months: mortality over the course 
of the programme in Highly Active Anti-Retroviral Treatment patients within the first 
6 months of treatment per initial CD4 category, with 4 categories of CD4 count: 
category 1= [0;50], category 2 = [51;100], category 3 =[101;200], category 4 = 
[>200], with CD4 count expressed in number of cells per mm3 
Mortality at +6 months of Highly Active Anti-Retroviral Treatment 
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Deaths were concentrated among patients who presented with extremely low CD4 
counts (below 50 cells/mm3). No deaths were recorded during this period among 
patients presenting with CD4 counts about 200. 
 
 
Notably, tuberculosis was a contributing factor. Almost 35% of registered patients 
had a history of TB. In Y2, 60% of patient deaths were directly attributable to TB as 
is clear from the data in Table 15. 
 
Table 15 Tuberculosis as a co-factor: ratio of Highly Active Anti-Retroviral 
Treatment patients presenting a current or past TB event 
All patients All 
Initial CD4 level  
<50 50-100 101-200 >200 
TB history 34.8% 56.5% 34.25% 23% 26.3% 
Source: PhD - VG 
 
Dead patients All Initial CD4 level 
<50 50-100 101-200 >200 
TB history 81.4% 81.6% 85% 75% No death 
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Figure 34 Mortality at + 12 months: mortality over the course of the programme in 
Highly Active Anti-Retroviral Treatment patients within the first 6 months of 
treatment per initial CD4 category, with 4 categories of CD4 count: category 1= 
[0;50], category 2 = [51;100], category 3 =[101;200], category 4 = [>200], with 
CD4 count expressed in number of cells per mm3 
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Not surprisingly, the mortality pattern remains the same, with no death for level 4 
patients (patients with an initial CD4 count > 200 cells/mm3), and most deaths 
occurring among patients with low CD4 counts. 
 
Level 1 (initial CD4 count below 50 cells/mm3) patients accounted for 54.3% of all 
deaths, and Level 2 (initial CD4 count in between 51 and 100 cells/mm3) patients for 
28.6%. Deaths did not increase substantially in the period between six and 12 months. 
Of the 419 patients that began HAART, 70 died, 81.4% of these within the first six 
months of therapy. 
 
The research suggests that patients with low CD4 counts were those who succumbed 
early in the programme, and most often with TB as a mortality co-factor. 
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 Financial unit-costs and Cost-effectiveness analysis 
Unit –costs 
Cost-effectiveness analysis 
Synergies 
Sensitivity analysis 
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Key findings 2 
Model cost-effectiveness analysis key findings 
VCT component cost-effectiveness 
! The VCT component proved cost-effective with an average ICR vs. the null set 
scenario of I$12 per DALY(3,0) averted. 
! Utilisation of capital investment seemed critical.  
Care & treatment component cost-effectiveness 
! The care & treatment component proved cost-effective with an average ICR vs. 
the null set scenario of I$252 per DALY(3,0) averted in term of real activity, 
and I$166 per DALY(3,0) averted with a theoretical occupation rate of 80%. 
! A limit of the model was essentially a late identification of People Living with 
HIV/AIDS registering to the clinic with advanced stage of HIV/AIDS, probably 
because of the social barriers mentioned in the introduction 
! Again, the utilisation of capital investment was critical in this result 
Synergies within the model 
! The return on capital items was critical and highly dependent on the utilisation 
of the structure 
! The outreach team by referring more than 66% of the clients tested helped 
bringing down dramatically unit-costs at VCT level, virtually offsetting its own 
costs. 
! The same was observed in between the VCT and the care & treatment 
component, especially in the early stage of the model implementation 
Conclusion 
Each analysed component is cost-effective when compared to international standards. 
This is mostly thanks to robust synergies within the outreach team, the VCT and the 
care & treatment components. The initial flow of clients generated by the outreach 
team helped drastically decreased unit-costs in the VCT and the care & treatment 
components. It appears that those synergies have limits. There are the HIV prevalence 
within the targeted population and the number of self-referred clients at registered at 
VCT level. Besides, the care & treatment component saw its cost-effectiveness level 
hampered by a low performance in term of medical outcome for the patients, mostly 
because of the late identification of PLHA registering to the clinic with advanced 
HIV/AIDS stages. 
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 Financial unit costs analysis 
 Mobile outreach team 
 Operating costs 
 
Figure 35  Mobile team costs: financial cost of the Outreach team over the course of 
the programme, with NGO’s and programme’s costs breakdown, in current US$ 
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Source: PhD - VG 
 
The annual operating costs of the mobile outreach team at programme level amounted 
to about US$11,500. Capital investment was minimal (motorbikes being the main 
expense incurred) and the team was set up quickly.  
 
The related costs incurred by MDM, however, were relatively high – on average 
twice the programme-level costs. In the first year of implementation the costs 
incurred by MDM were in fact three times that at programme-level. 
 Unit costs 
! Cost to contact one at-risk person 
Marginal costs (the extra cost needed to produce one extra “unit”, for instance to 
complete a testing procedure) were low and unit costs decreased quite dramatically 
over time from US$7.9 per contact to US$4.7 at the end of the three-year period (see 
Figure 36). 
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Figure 36  Mobile team's unit cost - cost per contact: financial cost in current US$ 
to contact one at-risk person, with NGO’s and programme’s costs breakdown 
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! Cost of referral: the three perspectives 
There are different ways to look at this unit cost, depending on the standpoint of the 
researcher. We propose three perspectives, each valid with regards to the angle of the 
analysis. 
 
Perspective 1 (Integral): in which the cost to refer a client for VCT is equivalent to the 
cost of contacting one at-risk individual. This unit cost reflects the combined tasks of 
the mobile outreach team prevention and harm reduction, and VCT referral activities. 
Because peer-educators are tasked with convincing at-risk persons to get a test when 
they contact them, prevention activities and referral are part of the same process, with 
a successful referral being a by-product of the general IEC process. 
 
Perspective 2 (VCT): in which the mobile outreach team's costs are related only to 
referred clients, as a way to calculate the extra cost generated as a result of the limited 
accessibility of the VCT service in the context of an alienating social climate. The 
mobile outreach team, in this perspective, contributes to boosting the activity of the 
VCT unit through attracting at-risk persons who wouldn’t otherwise access the 
service. 
 
Perspective 3 (medical). In this scenario, costs are spread among referred and positive 
clients, (in other words, future patients), as a way to reflect the additional costs   
generated by the necessity to identify people living with HIV and putting them on 
treatment in the context of limited social accessibility. 
 
Unit costs vary significantly depending on which perspective is being applied as is 
clear from the data in Figure 37, Figure 38 and Figure 39. 
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Figure 37  The integral perspective: outreach team’s financial cost in current US$ to 
refer one at-risk person to the VCT, with all Outreach’s costs spread over all 
contacted clients 
The "integral" perspective.  Cost to refer one at-risk person to 
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The unit cost to refer one case to VCT is US$4.7 in Y2. In the context of the limited 
financial resources available this is a significant sum. 
 
Figure 38  The VCT perspective: outreach team’s financial cost in current US$ to 
refer one at-risk person to the VCT, with all Outreach’s costs spread over referred 
clients 
The "VCT" perspective. Cost to refer one at-risk person to VCT
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Source: PhD - VG 
 
 
When the VCT perspective is considered, unit costs quadruple. The cost of referring 
one person for VCT in Y2 was US$18.70. Unit costs were influenced by the mobile 
outreach team's ability not only to contact at-risk persons, but also to convince them 
to get tested. As discussed previously, though the mobile outreach team was efficient 
in contacting clients from the programme's inception, it was later and following more  
training that the team recorded greater numbers of referrals to the VCT unit. 
Arguably, experience and training contribute to cost-efficiency in the long term. The 
data in Figure 18 clearly supports this: the unit cost to refer one client to VCT is 
almost US$86 in Year 0, while the average salary of a peer-educator is about US$90 
per month. We can conclude from these statistics that skilled peer-educators are 
critical to cost-efficiency.  
Figure 39  The medical perspective: outreach team’s financial cost in current US$ to 
refer one at-risk person to the VCT, with all Outreach’s costs spread over all 
positive-tested referred clients 
The "medical" perspective. Cost to refer one positive client to 
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When considering the third, “medical”, perspective (figure 39), costs appear 
extravagant. Surprisingly, in this context, the unit cost hits its lowest point not in Y2, 
when the project is nearing maturity, but in Y1, when both the numbers of clients 
referred and the HIV prevalence among them is high. As the prevalence diminishes 
among at-risk persons, the cost to identify one person living with HIV increases. The 
option of combining mobile outreach and VCT as one process might be considered 
but from a medical perspective this might well drive the unit cost higher as the 
prevalence rate decreases because of prevention efforts.  However, the cost of US$50-
$60 represents less than half the unit cost to treat one patient on ARVs for one year. 
This needs to be carefully balanced with the excellent outcome of HAART in a 
country in which only 25% of the PLHA have been diagnosed. 
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 VCT 
 Operating costs 
Total costs of the VCT unit are lower than those of the mobile team. This is 
attributable to the fact that VCT is much less labour-intensive. The slight increase in 
the costs in Y1 was the result of a renovation to the outpatient clinic (a financial cost 
which was not annualised).  
 
Figure 40  VCT costs: VCT financial cost in current US$ over the course of the 
programme, with NGO’s and programme’s costs breakdown 
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 Unit costs 
 Cost to test one client 
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Figure 41   Cost per test: financial cost in current US$ to proceed VCT on one client 
over the course of the programme, with NGO’s and programme’s costs breakdown. 
Evolution of the cost per client tested at Voluntary Counselling & 
Testing level
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Unit costs are quite low at the VCT level. A confirmation test, for example, averages 
about US$8.5 on average vs US$1.5 for a rapid-test. Of course the cost per client 
tested depends on the infection rate among clients tested because the Vietnamese 
National Guideline on VCT requires an ELISA test to confirm the initial quick-test.   
 
Testing a positive client cost out at an average of US$10 over the three-year period. 
The marginal cost for one positive test in the VCT unit is equivalent to the test cost 
itself. Taking into account the average level of activity in the VCT unit (about 40% of 
capacity) no additional capital or human resources are necessary.  Of course the cost 
could be decreased were the protocol to be changed and a double rapid test scheme 
adopted. This would bring down the cost to about US$3 per positive case detected. 
 
 
Table 16  The share of the direct costs in testing: evolution of the financial cost in 
current US$ to proceed VCT with one positive client over the course of the 
programme 
  Cost to test one positive client Y0 Y1 Y2 Average 
Programme 
Direct costs $35.61 $21.57 $12.86 $23.34 
Indirect costs $1.56 $1.10 $0.67 $1.11 
  Sub-total $37.17 $22.67 $13.53 $24.45 
NGO 
Technical support cost $14.79 $6.90 $5.77 $9.15 
NGO management and admin cost $69.34 $16.35 $10.83 $32.18 
  Sub-total $84.13 $23.25 $16.61 $41.33 
TOTAL $121.30 $45.92 $30.13 $65.78 
Source: PhD - VG 
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 Care & treatment 
 Operating costs 
   
Figure 42 C&T operational costs: financial cost in current US$ to run the care & 
treatment component over the course of the programme, with NGO’s and 
programme’s costs breakdown 
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Source: PhD - VG 
 
The global cost of the medical component of the programme was directly linked to 
the caseload of the clinic. A key marginal cost was medicines, such as ARVs and 
those used to treat aggressive opportunistic infections. 
 
Human resources were stable during the three-year period of programme 
implementation. There was some streamlining of the nutrition and adherence teams at 
the end of Y1, but otherwise no significant costs associated with staffing issues. One 
extraordinary cost was incurred because of the renovation of the OPC facility at the 
end of Y0, which accounts for the considerable increase in costs between Y0 and Y1, 
despite only a slight increase in caseload. 
 
 High costs 
Medicines are the critical component in HAART and these have contributed to 
increasing the cost of the care and treatment aspect of the programme (see Figure 43).  
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Figure 43 Medicines cost: evolution of the financial cost in current US$ of all 
medicines used at outpatient clinic level over the course of the programme 
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As the data in Figure 43 makes clear, the total expenditure for medicines tripled in 
three years, which is a lesser factor than expected considering the considerable 
increase in the number of active patients, this because of a major decrease in 
medicines market price. Medicines alone (but not their handling at clinic level) 
accounted for 44.5% of the total cost in Y0, and 48.7% in Y2. 
 
In Table 18 we outline the cost of selected regimens and drugs (per patient/per year) 
over the three-year period.  
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Table 17 Various medicines and regimens costs: examples of the evolution of the 
financial cost in current US$ of some selected HAART regimens over the course of 
the programme 
Cost for a one-year 
treatment Year 0 Year 1 Year 2 
D4T/3TC/NVP in 
fixed-dose 
combination 
Not available 101.29 USD 101.29 USD 
ZDV/3TC/NVP in 
fixed-dose 
combination 
Not available 239.53 USD 239.53 USD 
EFV 600 mg 1,533 USD 450.7 USD 239.31 USD 
3TC 150 mg 69.35 USD 50.97 USD 42.8 USD 
D4T 40 mg 58.66 USD 52.14 USD 52.14 USD 
NVP 200mg 438 USD 55.57 USD 43.44 USD 
Source: PhD - VG 
 Cost per patient per year 
Unit costs at patient level show a very interesting evolution, with a constant decrease 
overtime as the caseload of the clinic goes up and the price of medicines goes down. 
 
 
Figure 44 Pre-ARV patients costs: financial cost in current US$ of treating a pre-
Anti-Retroviral patient over the course of the programme, with NGO’s and 
programme’s costs breakdown 
Evolution of the cost per patient in the pre-ARV component
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Patients in the pre-ARV programme received little care from the clinic. Hence it is 
not surprising that the cost at OPC level was set quite low, (about US$46 in Y2, when 
the caseload allowed for a better return on the capital costs incurred (see Figure 45). 
 
 
Figure 45 ARV patient cost: financial cost in current US$ of treating a HAART 
patient over the course of the programme, with NGO’s and programme’s costs 
breakdown 
Average cost to follow-up a patient on ARV for one year
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Source: PhD - VG 
 
 
The cost per HAART patient per year is extremely high considering the context. 
Notably, the cost decreased significantly during the three-year implementation period. 
Still, during Y2, considered the best year in terms of cost, the amount spent on 
following up just one patient amounted to US$723. 
   
A closer look at the structure of the unit cost in Y2, as presented in Figure 46, reveals 
how critical was the pharmacy’s financial weight. 
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Figure 46 HAART patient cost breakdown: HAART patient follow-up and treatment yearly financial cost breakdown and structure in the last 
year of the programme, in current US$   
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 costs distribution among sub-components
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Hence the cost of drugs amounts to about half of the final cost of following-up a 
patient for one year. 
 
The second cost by importance was the medical team itself, followed by the 
laboratory (a CD4 count was worth 20 USD, viral load and virus genotype were not 
available in Hanoi at that time), the Home-Based Care, the adherence team, and the 
nutrition support component. 
 
Herein we simulated the cost of a patient whose CD4 count increases at least 100 
points after one year of HAART. We calculated this unit cost based on the 
“performance ratio” of the programme for each year, meaning its ability over the 
three-year period to raise the CD4 count significantly. This encompasses not only the 
impact of the ARVs, but also the capacity of the programme to limit mortality and 
deter inconsistent behaviour in patients during follow-up. On average, 38.3% of the 
patients who began HAART recorded such positive results (see Figure 48).  
 
 
Figure 47 The cost of an average performance: yearly financial cost in current US$ 
to have one patient seeing its CD4 count increases of at least 100 cell per mm3 after 
12 month of treatment, with all HAART medical costs spread over “succeeding” 
patients 
Average cost to have one patient increasing its CD4 count of at least 100 
points after 1 year of HAART
$0.00
$5,000.00
$10,000.00
$15,000.00
$20,000.00
$25,000.00
Timeline
C
o
s
t 
in
 c
u
r
r
e
n
t 
U
S
D
Outpatient Clinic costs $7,312.83 $3,394.03 $2,000.84 $4,235.90
non-governmental organisation
costs
$12,136.50 $3,890.85 $2,303.28 $6,110.21
Total $19,449.34 $7,284.88 $4,304.12 $10,346.11
Y0 Y1 Y2
Average of the 3 
years
 
Source: PhD – VG  
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This result is staggering considering the limited financial resources in the Vietnamese 
context. But it is the consequence of the combined constraints outlined in previous 
sections, and moreover to late referral/detections, CD4 counts that rendered patients 
ineligible for HAART and the lack of direct links between HIV and TB programmes 
in Vietnam.  
The research framework did not allow for the performance evaluation of either the 
HBC unit or the adherence team because of a lack of comparative programmes.  
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 Cost-effectiveness analysis of the model’s key 
components: VCT and care & treatment 
 
 Cost-effectiveness analysis of the VCT unit 
In this section we propose to calculate the cost per DALY(3,0) averted by the VCT 
unit, following WHO-CHOICE guidelines. 
 
Costs are computed: 
• using the ingredient approach; 
• capital items are annualised using a 3% discount rate; 
• local human resources costs are corrected using local minimal wages for 
unskilled labour; 
• international human resources costs are corrected using a standard rate 
corresponding to an average yearly cost of between US$72,000 and  
US$84,000 (2008 rates of exchange). These figures correspond to I$58,775  
and  I$68,571) per staff (which is the most important variation from financial 
costs). All costs are presented in 2000 International USD. All costs incurred to 
run the unit are included, not only costs corresponding to the testing of 
negative clients as we assume that testing both negative and positive clients is 
required to identify negative cases. 
 
We ran the simulation using the following variables: 
• No. of clients tested negative: 731 (result in Y2), corresponding to about 80% 
capacity use; 
• Sex-ratio: 56% (average in Y2); 
• Odds of any client becoming infected in the future: 30% (estimated rounded 
average prevalence according to the literature); 
• Disability weight factor for AIDS: 0.505; 
• Average life span after infection: 3 years; 
• Discounted life span (3%): 2.82; 
• Average age of the clients: 30 years; 
• Maximum life expectancy for a male: 80 years; 
• Maximum life expectancy for a female: 82.5 years; 
• Discounted remaining life expectancy for a male: 26.01 years; 
• Discounted remaining life expectancy for a female: 26.59 years; and 
• Ratio of avoided infections : 1%, 10%, and 24%. 
 
The results are presented in Table 18. 
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Table 18  Cost per DALY averted by the VCT: in function of the number of infection 
averted 
731 negative cases 
identified Null set 
Intervention – VCT DALY(3,0) averted 
Avoided infection ratio Avoided infection ratio 
1% 10% 24% 1% 10% 24% 
YLL 5134 4963 3423 1027 
182 1815 4357 YLD 312 302 208 62 
DALY(3,0) 5446 5265 3631 1089 
 
Cost per DALY(3,0) averted 
 
With Outpatient 
Clinic level costs 
Avoided 
infection rate 
of 1% 
47 I$/DALY(3,0) averted 
Avoided 
infection rate 
of 10% 
5 I$/DALY(3,0) averted 
Avoided 
infection rate 
of 24% 
2 I$/DALY(3,0) averted 
All costs included 
Outpatient Clinic 
+ non-
governmental 
organisation 
Avoided 
infection rate 
of 1% 
121 I$/DALY(3,0) averted 
Avoided 
infection rate 
of 10% 
12 I$/DALY(3,0) averted 
(mean assumption) 
Avoided 
infection rate 
of 24% 
5 I$/DALY(3,0) averted 
Source: PhD - VG 
 
 
The reality lies somewhere between these figures. The avoided infection ratio is based 
on an analysis operated in Africa (Kenya and South Africa), where the epidemic and 
social dynamics are quite different from those in Vietnam. Kenya and South Africa 
are experiencing a generalised epidemic, whereas Vietnam’s is concentrated among 
particular at-risk groups. Yet, we could transfer, though cautiously, the African 
experience, particularly in the case of the Tay Ho Clinic's VCT unit, where there is, 
on average, an extremely, regardless of whether clients belong to an at-risk group or 
not.  
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Comparison to international results 
The World Health Organisation-CHOICE offer sets of indicators on its website14. The 
index for VCT is: HIV-14: Voluntary counselling & testing [VCT] at 95% coverage. 
Its value is 40 I$/DALY averted. With an interval ranging from 5 to 121 I$, the Tay 
Ho VCT unit has the potential to meet WHO standards, especially considering its 
mean value of 12 I$/DALY(3,0) averted. 
 
As for the for the international literature, we find few comparable references:  
• a study in Tanzania and Kenya (Sweat 2000), demonstrates a range in 
Kenya of 5.16 to 27.36$ per DALY averted, and 6.58$ to 45.03$ in 
Tanzania;  
• a study performed in Tanzania (Thielman 2006) demonstrated a range 
from 4.72$ to 8.72$ per DALY averted; and  
• a study (Hogan 2005) reviewing different programmes in Asia and Africa 
reported an ICR of 40 I$/DALY averted for the World Health 
Organisation-SEAR (most likely the figure retained for World Health 
Organisation-CHOICE) 
 
It appears the Tay Ho model is comfortably in line with international standards, 
though, because of a lack of information in the papers cited, it is difficult to know 
how costs are allocated at managerial level, and/or what type of discount is used or 
not used in other research studies. Nonetheless, as demonstrated in the financial unit- 
cost discussion, the VCT unit largely benefits from the work of the mobile outreach 
team, especially during the first two years of the programme.  And it is very likely the 
client-base created by the mobile team continues to boost the cost-effectiveness of the 
model by decreasing fixed-costs per client (see Figure 48).  
 
                                                
14  http://www.who.int/choice/results/hiv_seard/en/index.html for results on HIV in the 
South-East Asia region. 
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Figure 48 Evolution of the cost-effectiveness of the VCT unit: economic cost in I$ to avert one DALY(3,0) based on the number of negative 
cases detected 
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Source: PhD - VG 
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 Cost-effectiveness analysis of the care & treatment component 
In this section we calculate the cost per DALY (3,0) averted by the care and treatment unit 
using the World Health Organisation-CHOICE approach. 
 
Costs were computed using the ingredient approach and followed those costs allocation 
and analysis methods:  
! Capital items were annualised using a 3% discount rate;  
! Local human resources costs were corrected using local minimal wages for 
unskilled labour; 
! International human resources costs were corrected using a standard rate 
corresponding to an average yearly cost of between US$72,000 and US$84,000 
(2008 exchange rate -  which translates to I$58,775 USD and I$68,571 
respectively) per staff ; and  
! Medicines costs were integrated using CIF costs, but without the cost of transport 
and storage at central level. All final costs are presented in International Dollars. 
 
To calculate years lived with disability (YLD), the disability weight for AIDS status was 
0.505, and 0.167 for HIV + Highly Active Anti-Retroviral Treatment (Burden of Disease 
2005).  
 
To calculate years life lost (YLL), we considered the maximum life expectancy for both 
males and females aged 30 years old using a time discount rate of 3% resulting in a YLL 
of 26.01 years for males and 26.59 for females. No age weight was used. The average life 
expectancy for AIDS patients without treatment was set at three years. 
 
The Immunology Case Registry was calculated versus the null set scenario.  
To determine the number of DALY averted we used the average caseload in Y2, with an 
annual performance from the programme of 38%. Thus, we considered only the patients 
who recorded CD4 counts above 200 OR with a net increase of 100 cells/mm3 after one 
year of treatment as a positive outcome. 
 
Table 19 DALYs averted by the C&T unit: economic cost in I$ to avert one DALY(3,0) in 
the care & treatment component 
General performance of 
38%, 135 males, 48 
females 
Null set Programme 
DALY (3,0) averted 
YLL 4239 2606 
YLD 260 470 
DALY (3,0) 4499 3076 1423 
Cost per DALY (3,0) averted 
With OPC level costs 98 I$/DALY (3,0) averted 
With Outpatient Clinic 
level cost + non-
governmental organisation 
costs 
252 I$/DALY (3,0) averted  
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Source: PhD - VG 
 
It is worth noting that the number of YLD is higher in the case of treatment. This is due to 
the fact that HAART bears a significant disability weight and a successful Highly Active 
Anti-Retroviral Treatment prolonged life adding Years of Life with Disability to the total. 
 
The cost per DALY averted is quite high, and more so when calculating NGO costs 
(which are significantly higher when using economic costs., Calculating real financial 
costs would cut down costs to US$190 per DALY averted). 
 
This result has to be compared to the international literature. However, for reasons 
previously discussed, little has been published on the matter. A paper from A. Renaud et al 
(2009), which offers a cost-effectiveness analysis of an OPC in Burundi, gives a result of 
US$258 (calculated at 2007 exchange rates), which is equivalent to 215 I$ per DALY 
(3,0) averted. The World Health Organisation-CHOICE gives an indication of 542 I$ in 
the SEAR-D region for HAART programmes. Yet this result was published in 2000 at a 
time when medicines were about four times in their price in 2008. Another paper from 
Shunsuke Ono et al (2006) proposes a value of US$610 per DALY in Thailand. So, based 
on limited comparisons the intervention could be considered cost-effective.. 
 
More helpful is the calculation of the potential cost-effectiveness of the programme 
according to two key factors: its average caseload, and its general performance. 
 
Results thereof are summarised in Figure 49 and 50. 
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Figure 49 Simulation of the cost per DALY averted: simulation of the economic cost in I$ per DALY(3,0) averted based on the average medical 
performance in the programme and its general caseload, with solely programme’s costs, and not NGO’s 
Cost per DALY (3,0) averted per number of patients on HAART with an overall 
performance of 10%, 30% and 70% (Economic costs, Outpatient Clinic costs only)
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Figure 50 Simulation of the cost per DALY averted with NGO costs: simulation of the economic cost in I$ per DALY(3,0) averted based on the 
average medical performance in the programme and its general caseload, with NGO’s and programme’s costs 
Cost per DALY (3,0) averted per number of patients on HAART with an overall 
performance of 10%, 30% and 70% (Economic costs, Outpatient Clinic and NGO 
economic costs)
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The maximum capacity of the OPC is pegged at 750 HAART patients. The average 
caseload (80% occupation) is 600 HAART patients, resulting in an ICER of 99 I$, 166 I$ 
and 500 I$ from 70% to 10 % of performance. To ensure cost effectiveness the site must 
be accessed by a minimum of 250 HAART patients. Authorities should be encouraged to 
favour integrated models such as the OPC at Tay Ho in efforts to save capital costs and 
promote effective management.  
 
Performance is also crucial. From 10% to 70%, ICER are divided by 5. It is nonetheless a 
confirmation of the past analysis using financial costs.  Clinical care quality is at stake, 
and ongoing training and medical supervision is necessary to improve the quality of 
diagnosis and treatment, yet as early access to the programme might be the most critical 
factor to consider. 
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 Synergies within the prevention component 
 
It is clear that the mobile outreach team has been at the forefront of attracting clients to the 
outpatient clinic. Important however is to analyse the possibility that the mobile team's 
operation could decrease the unit cost in such a context. 
 
If we compare the cost to test any client, (referred or not, tested positive or negative) to the 
complete cost to test and refer a client, (negative and positive included), the added cost for 
each referred client is not extravagant (see Figure 51). 
 
 
Figure 51   Cost for a referred client: financial cost in current US$ to proceed VCT on a 
referred with its cost of referral, vs. the financial cost in current US$ to simply proceed 
VCT on any given client over the course of the programme 
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Source: PhD - VG 
 
But if we considered the virtual unit costs at the VCT level in the absence of a mobile 
outreach team, the cost effectiveness of the team approach becomes clearer (see Figure 52 
and Figure 53). Over a three-year period, the mobile outreach team has directly generated 
66.2% of the VCT unit's traffic and helped improve the use of the capital invested in 
setting up the VCT site. 
 
As illustrated in Figure 52, the unit cost at VCT level is highly dependant on the inflow of 
clients because most of the unit's costs are fixed, such as human resources, facility and 
equipment. 
 
In Figure 53 and Figure 54 we compare the cumulative cost to test a referred client vs. the 
cost to test a self-referred patient. To calculate these unit costs, fixed costs are averaged 
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over the three-year period to reflect previous investments. Variable costs are extracted 
from Y2, after the streamlining exercise at the outpatient clinic. 
 
The data in Figure 53 are calculated based on the cost-per-contact unit cost at the mobile 
outreach team level to reflect the synergy between its general prevention functions and its 
referral mandate.  
 
In Figure 54, we compute the unit cost at the mobile outreach team level using its cost-per-
referral as a means to reflect the VCT perspective in the case that the mobile outreach 
team is designed only to identify and refer potential clients. 
 
From the data in Figure 53 it is clear that as long as the VCT unit does not receive more 
than 200 self-referred clients in a year, the added cost of the mobile outreach team 
diminishes the overall testing costs. 
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Figure 52  VCT unit cost simulation: financial cost in current US$ per client tested, programme’s costs only 
Voluntary Counselling & Testing related cost to test one client in function 
of the unit's yearly caseload
(with HIV prevalence=30%, 3Y average fixed-costs, and Y2 variable-costs per 
client tested)
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Source: PhD - VG 
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Figure 53  The impact of the Mobile team in VCT's unit cost: evolution of the financial cost in current US$ for contacting and testing a client 
in function of the caseload, and comparison of that financial cost vs. the financial costs in current US$ of various levels of self-referral 
Comparisons in between the cost per client tested in the absence of a Mobile Team Vs 
the cumulated cost to test one client referred by the Mobile Team, scenario 1
(in function of the number of self-referred patients Vs the No. of clients referred)
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Source: PhD - VG 
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Figure 54  The impact of the Mobile team on VCT's unit costs: evolution of the financial cost in current US$ for referring and testing a client 
in function of the caseload, and comparison of that financial cost vs. the financial costs in current US$ of various levels of self-referral 
Comparisons in between the cost per client tested in the absence of a Mobile Team Vs 
the cumulated cost to test one client referred by the Mobile Team, scenario 2
(in function of the number of self-referred patients Vs the No. of clients referred)
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Source: PhD - VG 
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The ceiling is obviously lower in the second than in the first scenario, with a level of 100 
self-referred clients per year. But the importance of the mobile outreach team's 
contribution to keeping start-up units costs low during the first two years of the 
programme cannot be underestimated.  
 
So the addition of the mobile outreach team helped reduce dramatically the unit-cost in the 
early phase of the programme at VCT level. Moreover, the role of the team  in prevention 
and harm-reduction activities among at-risk groups was an important asset in the model.  
 
Though setting up a mobile team purely to enhance the VCT component could be justified 
in the early phase of the programme, once the VCT unit was up and running,  the role of a 
mobile team for that specific purpose serves to drive up unit costs and so is questionable. 
Furthermore, the characteristics of the referred and non-referred clients differ little in 
terms of at-risk group belonging and HIV prevalence, meaning the qualitative added-value 
of the mobile outreach team in the long run could be at stake. Working with VCT clients 
as marketers (see Latkin 2005) of the VCT unit could be a very cheap and efficient 
strategy in the long-run. 
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 Synergies within the prevention and the Care & Treatment 
components 
Though the mobile outreach team and the VCT team worked with a significant degree of 
synergy, it appears that the synergy between the various components of the prevention and 
the care and treatment units of the programme was perhaps even more important in 
determining its cost-effectiveness, as the data in Figure 55 suggests. 
  
Figure 55 Identifying, testing and treating a PLHA: evolution over the course of the 
programme of the cumulative financial cost in current US$ of identifying, testing and 
treating for 1 year on HAART one patient 
Cumulative cost to identify (Mobile Team), test(Voluntary Counselling & 
Testing), and put 1 patient for 1 year on Highly Active Anti-Retroviral Treatment 
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Source: PhD - VG 
 
 
The cost to put a patient on HAART for one year decreased dramatically US$3,251 per 
year at OPC level (US$11,443 USD at NGO level) in Y0 to US$787 in Y2 (US$5,086 
USD at NGO level). This unit-cost decreased by a factor of four (4) over three years.  
This can be explained by the sizeable increase in the total number of clients reached, and 
tested, the number of patients on treatment, and the strong synergy between the 
components of the model. Medical costs in the absence of a mobile team would have 
exploded had the prevention unit been absent from the programme as the patient turnover 
certainly would have dropped dramatically. 
 
The mobile outreach team referred 70.6% of the positive clients tested at VCT level. 
Eighty-nine percent (89%) of the registered patients were processed through the VCT 
service and up to 63% of the patients on HAART were contacted by the mobile outreach 
team in the first place 
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The link in between those three elements, Mobile Team, Voluntary Counselling & Testing 
and Care & Treatment, is organic, and contributed to a decrease in the cost per patient 
contacted and cared for. 
 
In the first place it is very likely that the existence of the care and treatment site directly 
contributed to the prevention component. In the case of a positive test, the client could be 
offered prompt and comprehensive assistance.  This arguably was an attractive component 
of the programme (Maher 2007).  Comparisons across sites should be considered to 
support this hypothesis. Besides cost sharing, especially infrastructure and management 
between the mobile outreach team, the Voluntary Counselling & Testing unit and the care 
and treatment unit, contributed to the decrease in unit costs. 
 
Herein, we simulate the average unit cost to follow-up one ARV patient calculated on an 
average number of active patients to further explore that link. 
To do so, we split costs into two categories: fixed-costs and variable costs. Fixed-cost are 
independent from patient flow. Variable costs are dependent on patient flow.  
 
The fixed-cost categories encompass training, capital, and human resources that, in 
context, were fixed in size and not modified per patient flow. Variables costs comprised 
recurrent costs, other than salaries, medical tests, and medicines. 
 
To simulate the unit-cost, we worked from the fixed-costs average over the three years of 
implementation to reflect heavy capital investment at the end of Y0 and the beginning of 
Y1. We calculated variable costs for Y2, after the streamlining exercise undertaken at the 
clinic, to reflect the costs of the optimal organisational scenario. Costs were calculated 
following the same method as described in the methodology section. Key figures are 
reflected in Table 20. 
 
Table 20 Fixed and variable C&T costs 
 At pre-Anti-Retroviral 
level 
At Anti-Retroviral level 
Fixed-cost average US$1323.50  US$30,051.15 
Variable costs in year 
2, per patient per year US$62.87 US$509.78 
Unit-cost: cost per 
year per Anti-
Retroviral patient 
Unit-cost =  509.78 + (30,051.15)/ n 
n= average number of active patients in year 2 
Source: PhD - VG 
 
 
The results are presented in Figure 56 
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Figure 56 HAART unit costs and caseload: simulation of the financial cost in current US$ of treating for one year one patient on HAART in 
function of the caseload, with fixed costs averaged over the 3 years, and variable costs determined from the last year of implementation, 
programme’s costs only. 
Medical-costs to give HAART for one patient for one year, per average yearly caseload
(with 3Y average fixed-costs, and Y2 average variable-costs to put one patient on Highly Active 
Anti-Retroviral Treatment for one year)
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Figure 57 Impact of the MT and the VCT on the HAART unit costs: simulation of the financial cost in current US$ for putting one patient on 
HAART for one year, compared to that cost in the absence of the flow of patients generated by the Outreach team or the VCT. Programme’s 
costs only.  
Medical costs to give HAART for one patient for one year, per average yearly caseload
(with 3Y average fixed-costs, and Y2 average variable-costs to put one patient on Highly Active 
Anti-Retroviral Treatment for one year)
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Source: PhD - VG
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In Y2, the HAART component’s average caseload was 182.5 patients. In Y2, the cost to 
refer and test one positive client was US$73.18 (using the medical perspective cost 
calculation). An average of 411 active HAART patients were required to have the fixed-
cost per patient match that value assuming no extra capital was incurred to care for those 
patients.  
 
In Figure 54 we compare the cost to follow-up one patient on HAART for one year per 
average yearly caseload versus the unit-cost were the patients referrals from the mobile 
outreach team or the VCT unit discounted.  
 
If the mobile outreach team did not exist, the caseload would have been slashed by up to 
63%. If the same were true for the VCT unit, the figure would have been even higher 
(89%). Differences in unit-costs range from US$250 in the first scenario to US$1,300 
second scenario. 
 
In the case of the second scenario (no VCT), there would be a dramatic difference in terms 
of unit-cost. It could be argued that a strictly medical Outpatient Clinic with agreements 
with VCT sites could have attracted as many patients. Yet, those VCT centres without 
obvious links to HAART centres could have recorded much lower turnover. This was in 
fact the case in many standalone VCT and HAART sites in the country. 
 
In addition to attracting more patients to VCT, the synergy between the prevention and the 
medical components of the programme was highly effective in term of cost containment, 
fixed-costs return and general cost-effectiveness, though the global cost for one year is 
higher, and the management of such a model could be more complex. 
 
 Limits of the synergy 
The synergy between the prevention and the medical components is demonstrated in the 
context of a concentrated epidemic in an urban environment, such as Hanoi. 
 
Were the key patterns of the epidemic and the social context in Vietnam to change, the 
outcome could be entirely different. For instance, if the HIV prevalence among at-risk 
groups to decrease notably and the cost per People Living with HIV/AIDS identified 
would explode under such a model of action (see Figure 58). 
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Figure 58 MT unit costs and HIV prevalence: simulation of the financial cost in current US$ to identify one positive case among referred 
clients in function of the HIV infection rate among at-risk groups of population. Programme’s costs only. 
Mobile Team related costs to refer one positive client to the VCT according to 
the HIV prevalence of the target population
 (with n referred =601 (Y2), 3Y average fixed-costs, and average Y2 variable-costs 
per client referred and tested positive in Y2)
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We calculated the related costs incurred by the mobile outreach team to refer PLHA to 
VCT per the prevalence in the target at-risk groups. 
 
In Y2, the Mobile Team contacted 2376 at-risk persons, of which 601 went to the clinic 
for a test. One hundred and eighty-nine (189 or 31.4%)) of these tested positive. As 
mentioned in the upper sections, in Y2, using a medical perspective (identifying People 
Living with HIV/AIDS to put them on treatment), the average mobile outreach team 
related cost to identify one People Living with HIV/AIDS was US$59.65 using Y2 fixed-
costs (excluding testing costs) or US$87.07 using the three- year fixed-costs average 
(excluding testing costs).  
 
Yet, as clear from the data in Figure 58, the costs to identify PLHA for treatment would 
rises significantly from the from the point at which prevalence falls below 10%. With a 
prevalence of 10% among any group of population, the cost per identification rises to US$ 
210.95, US$392.91 at 5%, and a staggering US$1846.79 at 1%.  
 
Considering previous calculations based on the cost per patient per one year of HAART, 
were the prevalence within target groups to fall below 25% the HAART unit cost begin to 
rise. So the identification of potential patients in fact is at the expense of global cost-
effectiveness, a limit to that integrated model. 
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 Sensitivity analysis: costs scenarios according to key 
factors 
 Programme-dependent factors in the prevention component 
 Mobile and outreach team 
Prevention unit-costs are mostly determined by the ability of the mobile outreach team to 
convince at-risk persons to come to the centre to be tested. This ability varied greatly over 
the three years of implementation of the programme, from 9.2% of the contact in Y0, 
34.8% in Y1, and 25.3% in Y2, (137, 507 and 601 persons referred respectively). The 
possibility in this context to boost further referral figures, let alone the general legal 
framework regarding those specific target groups, is considered unlikely. External factors 
are most likely to drive the cost-effectiveness of that model as designed. 
 Voluntary Counselling and Testing (VCT) unit 
Unit-cost variations for this component of the programme would mostly rely on the 
average component caseload. With 1058 clients tested in Y2, the busiest of the three, the 
VCT counsellor had to deal with 2096 consultations a year, (175 consultations per month 
on average, or about 8 per day). We estimate that the capacity of the VCT unit as designed 
(one counsellor, one part-time lab nurse, low salaries) could handle 20 consultations a day 
(20 minutes per consultation, equivalent to  6.5 hours of consultation a day for a 8-hour 
workday), which translates to 2,787 clients a year (or 40% of capacity). 
 
The VCT unit costs depend largely on the use of fixed capital (see Figure 59).  
 
In Y2, (1056 clients), the cost per client tested reached US$13.56, with an average HIV 
prevalence of 30% among tested clients. At 80% of its capacity, (2230 clients per year), 
the cost would bottom out at US$8.30. This result would support the concentration of VCT 
centres in a given area. Because of stigma and discrimination, however, testing should be 
offered to clients at sites away from their immediate places of residence. 
 
Another variable that determines the cost per client tested is the prevalence among tested 
clients. It is common practice under Vietnamese law to confirm a first positive quick-test 
by an ELISA test. Whereas the cost to diagnose a negative case (in terms of test cost) is 
about US$1.50, a positive test adds US$9.5 in laboratory costs. 
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Figure 59 VCT unit cost and yearly caseload: financial cost in current US$ to test one client in function of the caseload, in a context of a 30% 
HIV infection rate among clients, average fixed-costs of the 3 first years, and variable costs of Y2. Programme’s costs only. 
Voluntary Counselling & Testing related cost to test one client in function 
of the unit's yearly caseload
(with HIV prevalence=30%, 3Y average fixed-costs, and Y2 variable-costs per 
client tested)
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Figure 60 VCT unit costs, yearly caseload and prevalence: financial cost in current US$ to test one client in function of the caseload, in a 
context of a 10, 30% or 50%  HIV infection rate among clients, average fixed-costs of the 3 first years, and variable costs of Y2. Programme’s 
costs only 
Voluntary Counselling & Testing related cost to test one client in function 
of the total No. of clients and their average HIV prevalence
(with HIV prevalence=30%, 3Y average fixed-costs, and Y2 variable-costs per 
client tested)
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The regulatory environment results in the cost per client tested being highly subject to 
the HIV prevalence of the population tested. Let’s assume that Vietnam managed to 
test 200,000 at-risk persons in one year (about its estimated drug-user population). 
With an average prevalence of 30%, test costs alone would run to US$870,000. In the 
case that the double quick-test method was used, the cost would decrease significantly 
to US$390,000 (about US$3 for a combined double quick-test to diagnose a positive 
case).  
 External factors 
As discussed previously, external factors impacting the cost-effectiveness of the 
programme are mostly the average prevalence among target groups, and above all the 
legal framework implemented in Vietnam targeting those groups. 
 
Figure 61 MT unit costs and HIV prevalence: simulation of the financial cost in 
current US$ to identify one positive case among referred clients in function of the 
HIV infection rate among at-risk groups of population. Programme’s costs only. 
Mobile Team related costs to refer one positive client to the VCT according to 
the HIV prevalence of the target population
 (with n referred =601 (Y2), 3Y average fixed-costs, and average Y2 variable-costs 
per client referred and tested positive in Y2)
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From a medical perspective, the necessity of a mobile outreach team to identify 
PLHA decreases with HIV prevalence.  
 
From a harm-reduction and testing perspective, were legislation to change, 
accompanied by the implementation of a widespread harm-reduction strategy, the 
HIV prevalence would plummet in at-risk groups, rendering the mobile outreach team 
obsolete. 
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Concurrently, and this is good news for the country, a Methadone Maintenance 
Therapy pilot programme has been ongoing since June 2007 in two cities: Haiphong 
and HCMC. The programme's reach is still limited (with fewer than 1,000 persons 
enrolled), but it could be a way to effectively combat the epidemic among the IDU 
sub-group, stabilise IDU's living with HIV/AIDS and enrolled in the HAART 
programme, decrease the use of injected heroin, and thus prevent new infections. 
 Programme-dependant factors in the medical component 
 
It appears the model fell short of its objective to retain patients before they were 
enrolled in the HAART programme, with a loss - temporary or permanent - of about 
27.5% in the pre-Anti-Retroviral sub-component. This group was of real concern 
because these were patients likely to return later the centre exhibiting symptoms of 
severe immune depression, and so impeding the efficacy of Highly Active Anti-
Retroviral Treatment. 
 
The HAART sub-component suffered as well from those defections and late arrival in 
term of disease development at the clinic as described later. 
 
The Home-Based Care component did not prove particularly effective in changing the 
general outcome of the medical component, and added an extra US$73.8 per patient 
per year to the cost of follow-up in the HAART component. Patients interviewed for 
this study reported positively on their visits with HBC workers. Such visits brought 
them comfort, and helped ease feelings of isolation. Yet it couldn’t address serious 
social cases, for instance when patients were abandoned or rejected by their families. 
Nor did it seem to boost adherence to treatment, or to the general protocol of the 
clinic. Related indicators had not changed seven (7) months after the HBC component 
was launched. The team was staffed by dedicated peer-educators who received 
extensive training and supervision, but they were not experienced in either social 
work or as professional para-medicals. Arguably, the model required them to  carry 
out too many different tasks to be efficient. In the absence of relevant comparisons, 
however, it is impossible to comprehensively determine the efficacy or relevance of 
the HBC team.  
 External factors 
Two key elements, in addition to the social accessibility of the programme discussed 
below, were critical in determining the global cost-effectiveness of the programme.  
The first was tuberculosis. The national TB programme is separate from the HIV 
programme in Vietnam, and there is limited integration of the two. Yet, TB was the 
leading associated factor in the deaths of HAART patients. More than 30 percent 
(34.8%) of the HAART patients had a history of TB, and 81.4% of those who died, 
did so from complications arising from TB. It would appear obvious then that 
integrating TB and HIV activities would be critical to improving cost-effectiveness. 
 
In Vietnam, TB-related mortality in HIV patients is influenced by early and effective 
diagnosis. Were TB properly diagnosed and treated, the mortality rate would decrease 
dramatically. In Y2, TB was directly responsible for 60% of the deaths of patients in 
the HAART programme. In the absence of TB, that figure would fall dramatically to 
5.44%. 
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Medicines cost was also critical. Though the cost of ARVs decreased sharply during 
the three-year period under review, it remained a significant cost to the programme 
(weighted as much as 48.73% of the total cost to follow-up one patient on HAART 
for one (1) year.  
 
 A central issue: the cost of social barriers/stigma 
According to our understanding of the situation, the stigma and social barriers that 
inhibit access to harm-reduction activities for at-risk persons and to care and 
treatment services for PLHA had a huge impact on the cost of the model, and 
generally on the cost of the combating HIV in Vietnam. Such barriers also inhibit the 
better use of resources, particularly in outreach and HAART treatment work. 
 
 At prevention and case-detection level 
Drug-use and sex-work in Vietnam are common, but dangerously stigmatized. Drug-
users, and commercial sex-workers alike are under the constant threat of being 
detained and forcibly removed to long-term rehabilitation centres. As a result, they 
are difficult to reach and complex to identify. This further impedes successful 
prevention and harm-reduction work.  
 
In Y2 it cost US$4.74 to contact one at-risk person, US$18.76 to refer one at-risk 
person for VCT, and US$59.65 to identify a PLHA. The addition of NGO-related 
costs boosted the unit costs of these respective activities to US$43.56, US54.93 and 
US$174.66. These were significant increases resulting, on the whole, from challenges 
in conducting outreach activities. However, the severe regulatory environment and the 
social stigma associated with IDUs and CSWs contributed to these inflated costs. 
Were the approach (both regulatory and social) to IDUs shifted from forced to 
voluntary rehabilitation, harm-reduction activities could be widely mainstreamed, 
decreasing rates of HIV prevalence among at-risk groups, as has been proven in 
Western countries and Thailand. 
 
The negative social barriers resulted, in Y2, in an additional cost of US$37.6 per 
PLHA registered in the programme (with the assumption that 63% of them were 
primarily identified by the mobile team), and US$110 for NGO-related costs, costs 
that should be offset by a change in the legal framework implemented in the country. 
 
The estimated HIV prevalence in Vietnam's general population is 0.45%, and this 
translates to about 360,000 People Living with HIV/AIDS out of 80,000,000 
Vietnamese citizens. About 60% of these are IDUs according to researches. The cost 
of detecting HIV in IDUs incurs an addition US$15,004,000, excluding overall 
management-related costs. 
 At medical level 
As is clear from the previous discussions, stigma and discrimination can be 
insurmountable obstacles to early access to services. More than half (52%) of patients 
who registered for HAART had a CD4 count below 200/mm3, and 26% recorded 
counts below 50. Delays in seeking comprehensive HAART had a catastrophic 
impact on the future of these patients. The average rate of mortality (at 6 months into 
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treatment) for patients with CD4 counts initially under 50 (Level 1) was 28.7%. 
Among patients with CD4 counts between 50 and 100 the rate was 15.7% and among 
those with CD4 counts above 200 the mortality rate was nil (0%). 
 
Figure 62 going above 200 CD4/mm3: evolution of the proportion of HAART 
patients with a CD4 count after 12 months of treatment above 200 cells per mm3 per 
initial CD4 count category over the course of the programme, with 4 categories of 
CD4 count: [0;50], [51;100], [101;200], [>200], and CD4 count expressed in 
number of cells per mm3 
Proportion of initiated patients with a CD4 count at +12 months above 200, 
per initial CD4 category
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Figure 63 the cost of the 200 CD4 line: one-year financial cost in current US$ to 
move or maintain a HAART patient’s CD4 count above 200 cells per mm3 after 12 
months of treatment, with 4 categories of CD4 count: category 1 = [0;50], category 2 
= [51;100], category 3 =[101;200], category 4 = [>200], with CD4 count expressed 
in number of cells per mm3 
Average cost per year to move or maintain one HAART patient above 200 
CD4/mm3, per initial CD4 category
(with the 3Y average performance rati, the 3Y average fixed-cost, and the Y2 
variable-costs, based on the average Y2 caseload)
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As clear from the data in Figure 62 and Figure 63, the cost to restore a reasonable 
CD4 count (above 200/mm3) after one year of HAART varied greatly depending on 
the initial CD4 count the patient recorded on registering for the programme. After one 
year on HAART, barely 8% of the patients with Level 1 CD4 counts showed signs of  
anything but severe immune-depression.  
 
In our simulation, cost per patient was calculated on the ratio of “successful” patients 
for each category to the average follow-up cost for patients according to their initial 
CD4 count. The unit-cost for Level 1 patients was nine (9) times higher than for Level 
4 patients, meaning nine times more resources were required for the programme to 
successfully treat and shift one patient from Level 1 status to a less compromised state 
of immune deficiency, than it was to do the same for a patient who began treatment at 
Level 4 status.  
 
Again social barriers and stigma contributed enormously to the lack of early access to 
treatment and thus impeded effective HAART.  
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 Discussion on the research’s hypothesises 
 
The underlying hypothesises supporting the implementation of that model of 
intervention combining prevention and care & treatment components proved true. The 
model promoted strong synergies, supporting the principle of integrated delivery of 
outreach, detection and care and treatment services.  
The model seems well suited to the local context in terms of efficacy. The integration 
of outreach, VCT and Highly Active Anti-Retroviral Treatment contributed to the 
increase in numbers of patients attending at the OPC level. Critical harm reduction 
activities could be carried out directly in the city’s hotspots as we know from other 
studies they are efficient (Des Jarlais 2007), while at the same time the mobile 
outreach team was identifying PLHA in need of a treatment. The concentration of 
these two functions within one team was certainly helpful. It reduced the cost per 
client referred for VCT, and helped to raise awareness of existing medical services 
offered by the OPC targeting directly the most at-risk populations.  
 
The integration saved costs, especially in the first years of the programme by boosting 
the demand for the clinic’s services. The VCT unit could rely on the presence of the 
care and treatment unit in the OPC to build the trust of clients and to offer HAART 
onsite, a rare service in Vietnam. The OPC also represented an important investment 
in terms of capital immobilisation, training, supervision, and networking. It would 
have made no sense to leave the space empty and the teams idle.  
 
Actually, the model worked as a system with positive feedback loops preventing new 
infections and actively treating identified People Living with HIV/AIDS through 
levelling off social barriers. Social stigma and barriers to access in Vietnam remain 
major obstacles to the generalisation of HIV/AIDS prevention and treatment 
operations in the context of a concentrated epidemic (Johnston 2006, Go 2006, 
Hammet 2007, Maher 2007, Nguyen 2008, Thanh 2009). Though further research is 
needed to support this conclusion, it is clear that the absence of strong and integrated 
service delivery would have had negative cost implications for the model. This system 
worked not only from outreach to treatment, but certainly as well from treatment to 
outreach by increasing VCT attraction, at-risk persons being aware of the presence of 
immediately free medical services within the same structure. 
 
A model in which outreach and detection services were not integrated with care and 
treatment service would have increased unit costs (by a factor of four (4)), resulting in 
the medical component running costs per DALY averted far below international 
standards. The same would have been the case had the VCT unit not been integrated 
with the mobile outreach service, at least in the first two (2) years of the programme's 
operation.   Integrating the mobile outreach team with the services offered by the 
VCT unit, cut costs to the latter by a factor of three (3).  
 
When the synergies emerging from the design of the programme are considered, the 
VCT service could be viewed as cost-effective against international standards. Using 
the approach developed by Sweat et al. (Sweat 2000), the average ICR of the VCT 
unit vs. the null set scenario was 12 I$/DALY(3,0) averted, well below World Health 
Organisation-CHOICE SEAR indicator of 40 I$. Yet, this figure is deemed at odd 
because no specific work on the matter has been conducted in the past in Vietnam, 
nor in Asia for that matter, to ascertain this estimate of 12 infections avoided for 
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every 100 negative tests.  Nonetheless, noted previously, the VCT unit benefited from 
the flow of clients provided by the mobile outreach service. Most of the costs incurred 
by the VCT unit were fixed and there is no doubt that the figure of 12I$/DALY(3,0) 
averted was arrived at as a result of the co-operation between the two prevention 
units. Of course, in the absence of the social barriers to access, this ICR would 
certainly be lower. Lower barriers imply higher caseloads and lower unit costs for this 
cost centre. 
 
Table 21 VCT DALY benchmarks 
Benchmarks – economic cost per DALY averted using mean infections 
avoided rate estimation from Sweat & al 
Tay Ho’s VCT 
department 
 
 
 
12 I$ 
 
 
 
 
 
 
 
 
 
 
 
5.16 to 27.36 I$ in Kenya 
6.58 to 45.03$ in Tanzania 
Sweat & al 
2000 
4.72 to 8.72$ in Tanzania Thielman 2006 
40 I$ in the South-East Asia 
region 
Hogan 2005 
– World 
Health 
Organisation-
CHOICE 
Source:PhD – VG 
 
Clearly the care and treatment unit could be considered cost-effective as well, thanks 
mainly to the integration of prevention services with the medical outpatient clinic. 
With an ICER vs. the null set scenario of 252 I$/DALY(3,0) using the real capacity 
utilisation, and 166 I$/DALY(3,0) averted with an 80% simulated capacity utilisation, 
the programme was well in line with international standards (see Table 22). 
 
Table 22 C&T ICER benchmarks 
Benchmarks – economic cost per DALY averted  
Tay Ho’s care 
and treatment 
department 
 
 
 
252 I$ 
with a 
real 
capacity 
utilisation 
 
166 I$ at 
80% of 
utilisation 
 
 
 
215 I$ in Burundi Renaud & al 2009 
610 I$ in Thailand Shunsuke Ono et Al 2006 
542 I$ in the SEAR 
World Health 
Organisation-
CHOICE 2000 
Source:PhD - VG 
 
Conclusion 
 
 120  
Yet, the global cost-effectiveness of the component was hampered by a low adherence 
to treatment protocols (a critical factor, see Oette 2006 and Ballif 2007,) and high rate 
of LTF as observed in other contexts (Mugusi 2009, Rougemont 2009, Tessema 2010, 
Hill 2010) , the delayed in identifying patients for testing and treatment, which 
impacts negatively on the overall medical performance of the programme (Braitstein 
2006, Johansson 2010), and possibly conservative guidelines used in Vietnam re 
Highly Active Anti-Retroviral Treatment eligibility criteria when earlier treatment 
upstart is more and more suggested (Bartlett 2009, Munderi 2010).  Nevertheless, as 
demonstrated in the sensitivity analysis, in the initial stage of the programme, the 
caseload was a more critical variable with regard to calculating the unit costs of the 
care and treatment cost centre, at least in the initial implementation phase of the 
programme.  
The performance of the medical programme remains the key variable. And it appears 
that to increase the performance levels from 40% to 70% would require dramatic 
changes in the environment in which the programme takes place: patients would need 
to be identified earlier, with better access to TB diagnosis and treatment – a critical 
aspect in the Vietnamese environment (Tran 2007, Goldfeld 2007), and access to 
Methadone Maintenance Therapy.  
Because two-thirds of the patients registered for HAART had a history of drug-use, 
and 50% of them were diagnosed with an initial CD4 count below 100 mm3, there 
was little to expect in term of their progress within the programme because the 
pathogenic system created by a severe legal framework (resulting in a low social 
accessibility to the programme), and limited access to addiction treatment, had not 
been addressed in the first place.  
 
 Limits of the model 
As discussed in the sensitivity analysis, the synergy depends on the context in which 
the programme operates. Were the prevalence in the target population to decrease 
below 15%, the synergy between the mobile outreach team and the VCT unit would 
begin to disappear. Moreover, were VCT services to be mainstreamed in Vietnamese 
society, the extra-cost incurred by the work of the mobile outreach team would hinder 
this synergy.  
 
Besides, because of contextual limitations the model showed only an average cost-
effectiveness by international standards, especially within its medical component. The 
model was unable to retain pre-ARV patients in sufficient numbers, or to convince 
them to abide by the OPC protocols in the absence of critical complementary services, 
such as Methadone Maintenance Therapy, and/or early access to ART. The 
introduction of a Methadone Maintenance Therapy in an environment in which about 
60% of PLHA are opiate-users would change dramatically the outcome of HAART, 
not to mention reducing HIV transmission.  
 
Yet, the main limiting issue of this model might be the intense technical support it 
needed to be implemented and supervised. 
Indeed, the presence of an external NGO, such as MDM, though necessary in the 
international co-operation scheme, added critical costs to that programme that, in the 
case of increased service delivery, have been diluted. Notwithstanding, the cost of 
essential medicines was, by far and away the greatest fixed cost incurred by NGO 
activity in this model.  
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Over three years, the share of NGO expenses was considerable, amounting to 58.1% 
of the total (see Figure 64). 
 
Figure 64 The financial weight of the NGO: the financial value of the action of 
Médecins du Monde over the 3 years of the programme 
Cost distribution in between the OPC and the non-
governmental organisation over the 3 years
$614,920.58
$442,857.19
Outpatient Clinic
level cost
non-
governmental
organisation
level cost
 
Source: PhD - VG 
 
 
 
The cost share to MDM was tremendous and reflected the complexity of setting up 
the programme in the Vietnamese environment. Particular cost considerations 
included: 
! channelling international funding; 
! financial control; 
! reporting to the fund source on both financial and performance aspects; 
! overall technical supervision of the model; and 
! local and international partners relationship, of which some critical such as the 
medicines management system set up in Vietnam by SCMS-MSH. 
 
General non-technical management and administration were the greatest costs 
incurred by MDM , as is clear from the data in Figure 65 and Figure 66. 
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Figure 65 NGO costs breakdown: distribution of Médecins du Monde’s financial 
costs in current US$ per key categories: social technical expertise, medical technical 
expertise, administration and general management 
non-governmental organisation cost structure over 3 years
$214,770.78
$208,311.57
$128,703.98
$63,134.25
Non-technical general
management
Administration
Medical expertise
Social expertise
 
Source: PhD -VG 
 
 
Figure 66 NGO costs distribution: share of each Médecins du Monde’s financial 
categories in percentage of the total, per key categories: social technical expertise, 
medical technical expertise, administration and general management 
non-governmental organisation cost structure over 3 years
Non-technical 
general 
management
35%
Administration
34%
Medical 
expertise
21%
Social expertise
10%
 
Source: PhD -VG 
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General co-ordination and administration functions accounted for as much as 69% of 
the total expenses incurred by MDM, reflecting the constraints around operating an 
international co-operation system within a local context. 
 
Costs also rose because the general co-operation system in Vietnam creates 
significant market distortions as a result of skilled labour being flooding niche job 
markets. All the MDM staff had to be fluent in written and spoken English, and also 
be computer literate. They had to be familiar with western management mechanisms, 
and have a specific skilled linked to their job description. On the technical side, 
MDM, along with other NGOs in the country, was constantly looking for local 
experts in the medical and the social domain, such as a medical doctor with a degree 
in public health and a strong command of HIV projects.  
 
As a consequence, combined unit cost and a NGO costs raised total costs significantly 
as shown in Table 23. 
 
Table 23 The NGO's share in key programme's unit costs 
Unit-cost designation Outpatient Clinic unit-cost 
Additional non-
governmental 
organisation 
level unit-cost 
Total 
Reaching an at-risk person 
by the mobile team $4.74 $9.15 $13.89 
Testing a Voluntary 
Counselling & Testing 
client 
$7.47 $9.16 $16.63 
Following-up for one year 
a pre-Anti-Retroviral 
patient 
$45.94 $55.40 $101.34 
Following-up for one year 
an Anti-Retroviral patient $665.95 $822.26 $1,488.21 
Increasing by 100 points 
after one year of Highly 
Active Anti-Retroviral 
Treatment an Anti-
Retroviral patient 
$1,841.16 $2,273.30 $4,114.46 
Source:PhD - VG 
 
 
It is likely that the international system in place inflated costs at the NGO level by 
creating not only job-market distortions, but also several time-consuming tasks, such 
as reports, proposal writing, seeking fund prolongation agreements, and juggling 
different accounting and report norms. The life cycle of an NGO is complex and 
resource-consuming because of the very nature of the system in which it operates. 
Programme management comes often second only to donor-related communication. 
 
It is not possible at this stage to thoroughly evaluate the impact on costs and 
performance of a different cooperation system, for instance one involving a direct 
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transfer of the funds to public authorities without the mediation on a NGO. It opens 
the field for additional research to assess different co-operation mechanisms and their 
impact on the quality and costs of programmes.  
 
As such, the question remains on how transfer both financial and technical burden to 
local authorities in a context of limited resources. 
The Vietnamese government spends US$1,100,000,000 on health care according to 
official figures from the National Office of Statistic, representing an expense per 
citizen of US$13.75, including general administrative costs. 
The sole medicine cost if the current number of PLHA (240,000) in Vietnam were to 
have access to first-line HAART rises to a minimum US$24,000,000 per year (or 3% 
of the total health budget), excluding medicines and management costs.  Apply the 
model’s average cost to follow-up a patient for one year of HAART, including 
medical management and biological follow-up in an optimal situation (average 
caseload of 750 patients), and that cost would exceed US$200,000,000 a year, (or 
almost 20% of the annual health budget). This excludes integrating general 
supervision and management costs, which, depending on the efficiency of the system 
put in place by the Vietnamese authorities, could add an extra 30% to the total. 
 
 Conclusion 
It seems that in the long term, the matter of the context and capital intensity are 
central.  
 
Though cost-effective when compared to international standards, and well adapted to 
the current constraints of the Vietnamese environment, the Tay Ho OPC approach is 
only a short-term solution until prevention and detection activities are mainstreamed 
and social obstacles lifted off. It could well be the best model to address HIV/AIDS in 
the Vietnamese context, or in any other places where concentrated epidemics are 
evident, yet at the expense of considerable technical assistance and associated costs 
resulting from the complexity of the management of such models of intervention.  
 
The situation of Vietnam, or similar countries, combining a lack of technical and 
financial resources and social obstacles to accessing at-risk populations poses the 
problem of long term sustainability of such actions. The coverage of prevention and 
treatment activities in Vietnam is still limited, and the scaling up of such an integrated 
model of intervention appears to be necessary to break the cycle of the epidemic. 
Nevertheless, the necessary resources to operate such integrated models of action 
when scaled up across a country would result in a probably unaffordable programme 
when compared to the more modest cost of lifting social barriers to care for at-risk 
and marginalized populations which will ease access to detection and harm-reduction 
activities, an hypothesis paving the way to further research on cost offsets and better 
ICR resulting from more accessible interventions, hence documenting the real cost of 
stigma and discrimination. 
 
Finally, the public health community should investigate further the cost of technical 
assistance of those integrated models of intervention based on the context of 
intervention, and should analyse the issue of technical management transfer and 
maintenance costs. This is a critical matter. Effective solutions exist and can be 
designed. Yet the issue of the capital intensity of such approaches, in the form of 
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technical skills and human resources appears to be a critical sustainability factor in 
settings where access to high quality human resource is scarce, notably at the public 
administration level when NGOs are competing to access and hire the most qualified 
persons, in a context of short funding cycles usually ranging from three to five years. 
Commodities such as medicines and laboratory tests saw their prices declining over 
the last 10 years. On the long run, the in-depth study of the cost-effectiveness of 
technical assistance itself should be at the core of future research programmes to now 
starting to document and review best practices to inform donors and implementers. 
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 The Tay Ho Outpatient Clinic’s components description 
 The prevention component 
The prevention component consists of two main elements: the mobile outreach team 
and the VCT unit. They work  in parallel to reach a common goal: to reduce HIV 
transmission in at-risk populations in Hanoi. The prevention component includes 
harm-reduction and behaviour change communication activities, voluntary testing,  
spreading general information about the epidemic and referring PLHIV to the care 
and treatment unit.  
The general population of the city is not a primary target of the programme, though 
services are open to anyone. 
 
 The mobile outreach team 
• Staff: the mobile outreach team is staffed mainly by peer-educators. Of a total 
of six team members, four are male IDUs and one is a female CSW. The sixth 
member is a male doctor-assistant.  
• Status: each staff member is salaried (paid by the clinic) 
• Tasks: the team undertakes the following tasks: 
o contact at-risk persons in the so-called hotspots of the city; 
o inform at-risk persons about the HIV epidemic; 
o engage in behaviour-change communication with the target 
population; 
o deliver prevention and harm-reduction material: free condoms and 
syringes, prevention leaflets; and 
o refer at-risk persons to the Tay Ho Outpatient Clinic for a free VCT 
• Hours: the mobile outreach team operates six evenings a week, from 7pm to 
11pm. The team's primary mode of transport is the motorbike.  
• Role of MDM: The role of MDM in respect of the mobile outreach team is to: 
o organise communication training; 
o support the team in its hotspot-mapping process; 
o support the team in its monitoring and evaluation (M&E) efforts;  
o support the outpatient clinic’s management in supervising and 
evaluating the performance of the team; and 
o help coordinate the team with other groups in the city, and within the 
clinic. 
The technical office at MDM level in charge of this component is the social project 
officer, or SPO. 
 
 The Voluntary Counselling and Testing (VCT) unit 
• Staff: the VCT department is staffed by one retired female doctor-assistant 
performing the task of VCT counsellor. The department receives the support 
of the laboratory. A nurse, partly dedicated to the VCT department, and partly 
to the care and treatment unit, is in charge of the testing phase. She draws 
blood samples, operates the first quick-test, and refers the sample if necessary 
to a certified laboratory in the city. A laboratory-technician was employed for 
20 months of the programme to support the nurse. This position was closed 
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during a streamlining process. 
• Status: both the VCT counsellor and laboratory nurse operate full-time and 
are salaried by the programme.  
• Tasks: the VCT counsellor is in charge of the pre- and post-test counselling 
session. The VCT in the outpatient clinic is anonymous (clients are registered 
under a code), and free of charge. The pre-test and the test are done during the 
same session, and the post-test session takes place seven (7) days thereafter, 
on receipt of the confirmation test from the laboratory. Clients with negative 
results on the first quick-tests do not receive their results on the same day of 
the quick-test, because the aim is to treat all clients equally. The official 
protocol in Vietnam requires an ELISA confirmation test for any positive 
quick-test. Double quick-tests protocols are not permitted. 
• Hours: the VCT department operates Monday-Friday, 8.30am - 12.30pm, and 
2pm - 5pm 
• Role of MDM: the department is under the supervision of the MDM's medical 
team. Its tasks include:  
o co-ordinating external training sessions; 
o on-the-job training; 
o monitoring and evaluation support; and 
o supporting the clinic’s management in co-ordinating the work of the 
department with that of the mobile outreach team and the care and 
treatment unit, as well as ensuring quality control at the laboratory 
level. 
 The care and treatment department 
The outpatient clinic offers a comprehensive service to registered patients, from 
adherence training and support to home-based care and HAART. All services are 
provided free of charge,  including routine biological and morphological tests 
(ultrasound, X-Ray, scanner). Hospitalisations for severe opportunistic infections are 
generally not covered by the programme, unless exceptional cases arise. 
 
 The medical unit 
The medical unit is in charge of the medical follow-up of the patients, from initial 
clinical and biological staging to HAART.  
! Staff: in the early stages of the programme the unit was staffed by one full-
time nurse and one part-time medical doctor. As the number of patients 
increased, another medical doctor was hired on a part-time basis.  
! Status: the nurse is employed full time by the programme. The full-time 
doctor is deployed from the public service and receives an allowance from the 
programme, and the part-time doctor is recently retired and receives a salary 
from the programme 
! Tasks: The team is in charge of the staging of the patients and their medical 
follow-up, both biological and clinical. Routine check-ups are programmed 
per the Vietnamese national guidelines for care and treatment: pre-ARV 
patients are examined every six (6) months, with a CD4 count, patients on 
HAART are examined every month and their CD4 counts are tested every six 
(6) months. Any patient developing opportunistic infections is welcome to 
come to the clinic to receive a free examination and free treatment. Patients 
on HAART are seen at the clinic on average three (3) times a week during the 
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first month of treatment. Patients are closely monitored and the ARV 
selection committee, consisting of the two clinic doctors, the director of the 
clinic and members of the adherence team, review each case and decide when 
patients should begin HAART. 
! Hours: the team is on duty during office hours, Monday-Friday. They are 
also accessible to patients by phone in case of an emergency occurring after 
close of business  
! Role of MDM includes: 
o training design and implementation; 
o referral network building; 
o quality of care assessment; 
o on-the-job training; 
o M&E support; 
o supporting clinic management in co-ordinating the work of the 
medical unit with the other care and treatment units: and 
o connecting the centre with other centres in the city. 
The technical office at MDM level in charge of this component is the Medical Project 
Officer (MPO), including the medical co-ordinator.   
 
 The nutrition unit 
The nutrition unit existed only temporarily for 20 months in the first phase of the 
programme. It was terminated because the service (nutrition support to patients, and 
nutrition training) was not popular among patients, and quite costly. Nutrition training 
has been absorbed by the adherence team, as a part of the pre-ARV training 
curriculum. 
! Staff: in the early stages of the programme, the unit was staffed with one full-
time nutritionist, supported during the cooking sessions by the clinic’s 
receptionist. 
! Status: The nutritionist was a salaried employee. 
! Tasks: The nutrition team was in charge of training patients about nutrition 
and HIV, including basic general nutrition training, ARVs and food, and how 
to adapt diet to cope with AIDS symptoms. The team provided cooking 
courses to patients and their care-givers and was responsible for the 
preparation of daily meals for the weakest and poorest patients registered in 
the programme. Ironically it was the latter service that proved unpopular with 
patients, despite the fact that many of them were obviously undernourished. 
! Hours: the nutrition team was on duty during office hours, Monday-Friday. 
! Role of MDM included: 
o training design and implementation; and 
o referral network building; M&E support. 
The tasks were  carried out by the medical team’s assistant. 
 
 The adherence unit 
The adherence unit is a critical component in an environment in which 60% of the 
patients are active IDUs. 
! Staff: in the early stages of the programme, the unit was staffed by two part-
time medical doctors. Two years (24 months) after the clinic's streamlining 
exercise was implemented the two MDs were replaced by a new team 
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consisting of a retired doctor-assistant, a peer-educator who was on ARVs, 
and a former member of the HBC team. 
! Status: The two medical doctors were deployed staff and received a stipend 
from the programme. After streamlining, the replacement team is working 
full-time for the programme, and members receive salaries accordingly. 
! Tasks: The adherence unit team has two essential tasks: 
o pre-ARV adherence training: this consists of a formal training 
course of six (6) sessions: three (3) in-group with a care giver, and 
three (3) individual. The objectives of the course are to prepare future 
ARV patients for  the possible repercussions of treatment, including 
side-effects, the risk of resistance, adherence to treatment, and  
nutrition guidelines. The training takes place over three (3) weeks, 
with two (2) meetings a week. Patients with CD4 counts below 50 do 
not have to follow the course and qualify for the so-called “fast track” 
ARV procedure, which is given seven (7) days after the CD4 count 
test is released. After patients finish the training, their cases are 
reviewed by the ARV selection committee for final validation. 
o Anti-Retroviral patients follow-up: the team receives requests from 
the medical unit to follow up patients suspected of poor adherence. 
Members of the team undertake to reinforce adherence messages. 
Patients considered at high risk of low adherence to treatment are 
followed-up on a regular basis by the adherence team, in conjunction 
with the HBC team. 
! Hours: the adherence team is on duty during office hours, Monday-Friday. 
! Role of the MDM includes: 
o training design and implementation; 
o referral network building; and 
o M&E support. 
The technical office at MDM level in charge of this component is the MPO, including 
the medical co-ordinator. 
 The home-based care (HBC) team 
The home-based care team was created eight (8) months into the programme as a way 
to reinforce patient support and follow-up and to prolong care at home. 
! Staff: All peer-educators are recruited from the clinics patients' pool. The 
HBC team averages six (6) members, of whom 5 are peer-educators, initially 
mostly former IDUs. For management reasons (including problems of HBC 
peer-educators using and dealing drugs onsite) the home-based care peer-
educators were replaced by non-IDU patients of the clinic.  
! Status: The five (5) peer-educators are employed full-time by the programme 
and receive salaries. The doctor-assistant is deployed from the public sector, 
works part time and receives an allowance.  
! Tasks: The team is in charge of the home follow-up of HAART patients, and 
particularly patients with severe medical conditions. The team's tasks range 
from basic psychological support, social status evaluation, to adherence 
follow-up and basic medical check-ups 
! Hours: the HBC team in on duty office hours, Monday-Friday, in the field at 
patients’ homes 
! Role of MDM includes: 
o training design and implementation; 
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o on-the-job training; 
o supporting the clinic management to co-ordinate the work of the HBC 
team with the rest of the care and treatment programme; and 
o M&E support. 
The technical office at MDM level in charge of this component is the medical 
coordinator, including the MPO.  
 The pharmacy 
The pharmacy is an essential part of the care and treatment unit because it dispenses 
all medicines, and undertakes the general logistics of the department. The pharmacy is 
located in the clinic and is required to handle essential medicines dispensing duties. 
Medicines are ordered from an international NGO consortium, Medicine Science for 
Health - Supply Chain Management System (MSH-SCMS), which operates in 
Vietnam under the auspices of PEPFAR. The MSH-SCMS is also in charge of 
certifying the unit in terms of drug dispensation, storage, and inventory. 
! Staff: initially the pharmacy was staffed by one part time pharmacist 
assistant. Later a pharmacist was hired to support the assistant. 
! Status: both the pharmacist and the pharmacist-assistant are deployed from 
the public sector and receive an allowance. 
! Tasks: The pharmacy team is in charge of dispensing medicines to patients - 
primarily ARVs and drugs to treat opportunistic infections, controlling the 
medicines stock, and passing purchase orders regarding small medical 
consumables used by the care and treatment unit.  
! Hours: the pharmacy team is on duty during office hours, Monday-Friday. 
! Role of MDM includes: 
o training design and implementation; 
o on-the-job training; 
o supporting the unit in terms of quality control (mostly drug 
dispensation, and storage); 
o supporting the clinic’s management in co-ordinating the work of the 
unit with that of the care and treatment component of the programme; 
o M&E support; and 
o Cross-checking inventory with the reported number of patients 
receiving medicines. 
The technical office at MDM level in charge of this component is the medical co-
ordinator, including the MPO.  
 The laboratory 
The laboratory is a minor unit in charge of performing the VCT quick-tests, collecting 
blood samples for patients and occasionally administering vaccines. Apart from the 
HIV quick-tests, no real lab work occurs. All blood samples are sent to off-site 
referral laboratories. 
! Staff: One laboratory nurse, and one laboratory technician were employed in 
the initial stages of the programme. The latter position was closed 20 months 
into the programme, following a streamlining exercise.  The laboratory nurse 
works for both the care and treatment unit and the VCT unit. 
! Status: The laboratory technician was deployed from the public sector and 
received an allowance. The laboratory-nurse is fully employed by the 
programme and receives a salary. 
! Tasks: The laboratory is solely in charge of drawing blood specimens, which 
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are later referred to a certified laboratory, specifically for CD4 count testing. 
No advanced test needing laboratory techniques such as microscopy are 
undertaken onsite. Blood is drawn at the clinic for the comfort of the patients.  
! Hours: the laboratory operates office hours, Monday-Friday 
! Role of MDM includes: 
o training design and implementation; 
o on-the-job training; 
o supporting the unit in term of quality control (mostly blood-sample 
storage); 
o supporting the outpatient clinic’s management to co-ordinate the work 
of the unit with that of the care and treatment component of the 
programme; and 
o M&E support. 
The technical office at MDM level in charge of this component is the medical co-
ordinator, including the MPO  
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 Financial costs of the principal cost centres at Outpatient 
Clinic level 
 
 
   Y0 Y1 Y2 Total 
Mobile team 
Programme's 
costs 
Direct $8,901.15 $6,026.69 $8,430.02 $23,357.86 
Indirect $2,843.07 $6,038.47 $2,806.37 $11,687.91 
Sub-total $11,744.22 $12,065.17 $11,236.39 $35,045.77 
NGO's costs 
Direct cost $7,505.22 $7,981.64 $9,860.35 $25,347.21 
Indirect cost $24,255.15 $11,194.28 $11,352.87 $46,802.30 
Sub-total $31,760.37 $19,175.92 $21,213.22 $72,149.51 
TOTAL $43,504.58 $31,241.09 $32,449.61 $107,195.28 
       
   Y0 Y1 Y2 Total 
Voluntary 
Counselling 
& Testing 
and 
laboratory 
related costs 
Programme's 
costs 
Direct $5,319.80 $6,391.60 $6,484.42 $18,195.81 
Indirect $1,461.32 $3,706.52 $1,394.47 $6,562.31 
Sub-total $6,781.12 $10,098.11 $7,878.89 $24,758.12 
NGO's costs 
Direct cost $2,538.85 $2,882.08 $3,115.12 $8,536.05 
Indirect cost $12,165.22 $6,921.65 $5,888.04 $24,974.91 
Sub-total $14,704.07 $9,803.73 $9,003.15 $33,510.96 
TOTAL $21,485.19 $19,901.84 $16,882.05 $58,269.08 
       
   Y0 Y1 Y2 Total 
Care & 
treatment 
Programme's 
costs 
Direct $53,106.55 $98,491.23 $124,967.23 $276,565.02 
Indirect $9,887.42 $26,926.20 $15,491.75 $52,305.37 
Sub-total $62,993.97 $125,417.44 $140,458.98 $328,870.39 
NGO's costs 
Direct cost $18,845.29 $45,715.03 $55,607.61 $120,167.93 
Indirect cost $87,405.16 $98,126.37 $106,093.73 $291,625.26 
Sub-total $106,250.45 $143,841.40 $161,701.35 $411,793.19 
TOTAL $169,244.42 $269,258.84 $302,160.33 $740,663.58 
       
   Y0 Y1 Y2 Total 
Social 
activities 
Programme's 
costs 
Direct $16,047.09 $14,941.04 $16,558.51 $47,546.64 
Indirect $1,708.07 $3,522.26 $2,009.02 $7,239.35 
Sub-total $17,755.16 $18,463.29 $18,567.53 $54,785.99 
NGO's costs 
Direct cost $8,800.57 $12,984.46 $16,002.01 $37,787.03 
Indirect cost $23,767.98 $17,590.20 $18,321.71 $59,679.88 
Sub-total $32,568.55 $30,574.66 $34,323.71 $97,466.92 
TOTAL $50,323.70 $49,037.95 $52,891.25 $152,252.91 
 
 
 
Grand total for 3 years : 1,058,380 2008-USD 
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 Financial costs of the cost centres’ sub centres at OPC 
level 
 
   Y0 Y1 Y2 Total 
Home-Based 
Care 
Programme's 
costs 
Direct $2,140.98 $5,234.58 $9,469.82 $16,845.38 
Indirect $2,356.58 $8,896.60 $4,033.77 $15,286.96 
Sub-total $4,497.56 $14,131.18 $13,503.59 $32,132.34 
NGO's costs 
Direct cost $899.74 $4,633.24 $5,318.04 $10,851.02 
Indirect 
cost $4,525.96 $10,574.62 $10,094.21 $25,194.80 
Sub-total $5,425.70 $15,207.87 $15,412.25 $36,045.82 
TOTAL $9,923.27 $29,339.04 $28,915.84 $68,178.15 
       
   Y0 Y1 Y2 Total 
Laboratory 
Programme's 
costs 
Direct $5,172.37 $14,628.21 $22,089.97 $41,890.55 
Indirect $1,842.88 $4,946.10 $1,965.93 $8,754.91 
Sub-total $7,015.25 $19,574.31 $24,055.90 $50,645.46 
NGO's costs 
Direct cost $2,784.12 $6,829.03 $9,558.84 $19,171.99 
Indirect 
cost $13,556.57 $14,869.80 $18,183.88 $46,610.24 
Sub-total $16,340.68 $21,698.83 $27,742.72 $65,782.23 
TOTAL $23,355.93 $41,273.14 $51,798.62 $116,427.69 
       
   Y0 Y1 Y2 Total 
Pharmacy 
Programme's 
costs 
Direct $32,850.64 $65,479.30 $75,472.26 $173,802.20 
Indirect $1,424.76 $4,031.56 $4,366.36 $9,822.68 
Sub-total $34,275.40 $69,510.86 $79,838.62 $183,624.88 
NGO's costs 
Direct cost $6,985.75 $26,801.17 $31,532.35 $65,319.26 
Indirect 
cost $31,741.02 $56,006.33 $60,441.93 $148,189.28 
Sub-total $38,726.77 $82,807.50 $91,974.28 $213,508.54 
TOTAL $73,002.17 $152,318.36 $171,812.90 $397,133.42 
       
   Y0 Y1 Y2 Total 
Adherence 
Programme's 
costs 
Direct $883.53 $1,975.50 $2,622.78 $5,481.81 
Indirect $854.19 $2,276.77 $1,467.68 $4,598.64 
Sub-total $1,737.72 $4,252.27 $4,090.46 $10,080.45 
NGO's costs 
Direct cost $789.31 $1,150.19 $1,613.47 $3,552.96 
Indirect 
cost $3,801.75 $2,883.77 $3,066.93 $9,752.45 
Sub-total $4,591.06 $4,033.96 $4,680.40 $13,305.41 
TOTAL $6,328.78 $8,286.23 $8,770.86 $23,385.86 
       
   Y0 Y1 Y2 Total 
Nutrition Programme's costs 
Direct $2,410.09 $4,699.51 $343.07 $7,452.67 
Indirect $872.48 $1,244.22 $16.00 $2,132.70 
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Sub-total $3,282.57 $5,943.74 $359.07 $9,585.37 
NGO's costs 
Direct cost $652.19 $1,910.47 $144.57 $2,707.23 
Indirect 
cost $3,964.06 $4,422.23 $282.00 $8,668.29 
Sub-total $4,616.25 $6,332.70 $426.57 $11,375.52 
TOTAL $7,898.82 $12,276.44 $785.64 $20,960.89 
   Y0 Y1 Y2 Total 
Medical team 
Programme's 
costs 
Direct $11,023.68 $10,332.39 $19,465.66 $40,821.73 
Indirect $3,031.95 $6,923.25 $4,045.82 $14,001.02 
Sub-total $14,055.63 $17,255.64 $23,511.48 $54,822.75 
NGO's costs 
Direct cost $7,454.17 $6,060.29 $9,380.16 $22,894.61 
Indirect 
cost $33,548.97 $13,125.35 $17,674.82 $64,349.13 
Sub-total $41,003.14 $19,185.63 $27,054.98 $87,243.75 
TOTAL $55,058.77 $36,441.27 $50,566.46 $142,066.50 
 
 
 
 Financial costs of the cost centres at non-governmental 
organisation level 
 
 
 Y0 Y1 Y2 Total 
Indirect costs General coordination $79,884 $61,517 $73,369 $214,771 
Administration $67,710 $72,315 $68,287 $208,312 
Direct costs Medical coordination $21,384 $48,597 $58,723 $128,704 Social coordination $16,306 $20,966 $25,862 $63,134 
Total $185,283 $203,396 $226,241 $614,921 
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 Economic costs at Outpatient Clinic level 
 
  Economic costs, fixed and variable, with a Y2 level of activity 
  Outpatient Clinic level cost 
non-
governmental 
organisation 
level cost 
Total 
MT 
direct cost $22,417.32 $14,429.91 $36,847.24 
indirect cost $1,210.92 $22,808.05 $24,018.96 
total $23,628.24 $37,237.96 $60,866.20 
VCT 
direct cost $4,230.83 $2,560.12 $6,790.94 
indirect cost $228.54 $4,206.74 $4,435.27 
total $4,459.36 $6,766.85 $11,226.22 
MED 
direct cost $28,132.50 $17,023.27 $45,155.77 
indirect cost $1,519.63 $27,972.32 $29,491.95 
total $29,652.13 $44,995.59 $74,647.72 
LAB 
direct cost $20,532.03 $12,424.15 $32,956.18 
indirect cost $1,109.08 $20,415.13 $21,524.20 
total $21,641.11 $32,839.28 $54,480.38 
PHA 
direct cost $64,240.17 $38,872.41 $103,112.59 
indirect cost $3,470.06 $63,874.41 $67,344.47 
total $67,710.23 $102,746.82 $170,457.05 
HBC 
direct cost $20,029.71 $12,120.19 $32,149.91 
indirect cost $1,081.94 $19,915.67 $20,997.62 
total $21,111.66 $32,035.86 $53,147.52 
NUT 
direct cost $1,659.92 $1,004.44 $2,664.36 
indirect cost $89.66 $1,650.47 $1,740.14 
total $1,749.59 $2,654.91 $4,404.49 
ADH 
direct cost $5,877.27 $3,556.40 $9,433.66 
indirect cost $317.47 $5,843.80 $6,161.27 
total $6,194.74 $9,400.20 $15,594.94 
IGA 
direct cost $2,498.00 $1,607.95 $4,105.95 
indirect cost $134.93 $2,541.54 $2,676.47 
total $2,632.93 $4,149.49 $6,782.42 
Social 
sup+OVC 
direct cost $2,604.09 $1,676.24 $4,280.32 
indirect cost $140.66 $2,649.47 $2,790.14 
total $2,744.75 $4,325.71 $7,070.46 
Club 
direct cost $5,278.95 $3,398.03 $8,676.98 
indirect cost $285.15 $5,370.96 $5,656.11 
total $5,564.10 $8,768.99 $14,333.09 
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  Fixed economic costs 
  Outpatient Clinic level cost 
non-
governmental 
organisation 
level cost 
Total 
MT 
direct cost $18,579.46 $13,323.95 $31,903.42 
indirect cost $2,060.85 $20,354.61 $22,415.46 
total $20,640.32 $33,678.56 $54,318.88 
VCT 
direct cost $3,902.11 $2,491.75 $6,393.86 
indirect cost $432.83 $4,091.20 $4,524.02 
total $4,334.94 $6,582.94 $10,917.88 
MED 
direct cost $20,382.74 $13,015.68 $33,398.42 
indirect cost $2,260.88 $21,370.43 $23,631.30 
total $22,643.61 $34,386.11 $57,029.72 
LAB 
direct cost $3,773.22 $2,409.44 $6,182.66 
indirect cost $418.53 $3,956.06 $4,374.59 
total $4,191.75 $6,365.50 $10,557.24 
PHA 
direct cost $3,359.15 $2,145.03 $5,504.18 
indirect cost $372.60 $3,521.92 $3,894.52 
total $3,731.75 $5,666.95 $9,398.70 
HBC 
direct cost $16,249.25 $10,376.18 $26,625.43 
indirect cost $1,802.38 $17,036.64 $18,839.03 
total $18,051.63 $27,412.82 $45,464.46 
NUT 
direct cost $1,526.08 $974.50 $2,500.58 
indirect cost $169.27 $1,600.03 $1,769.30 
total $1,695.35 $2,574.53 $4,269.88 
ADH 
direct cost $5,225.14 $3,336.59 $8,561.73 
indirect cost $579.58 $5,478.34 $6,057.92 
total $5,804.72 $8,814.93 $14,619.65 
IGA 
direct cost $2,498.00 $1,791.40 $4,289.40 
indirect cost $277.08 $2,736.67 $3,013.75 
total $2,775.08 $4,528.07 $7,303.15 
Social 
sup+OVC 
direct cost $406.26 $291.34 $697.60 
indirect cost $45.06 $445.07 $490.14 
total $451.32 $736.41 $1,187.73 
Club 
direct cost $5,278.95 $3,785.71 $9,064.66 
indirect cost $585.55 $5,783.32 $6,368.86 
total $5,864.49 $9,569.02 $15,433.52 
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  Marginal economic costs per extra unit of activity for each sub-cost centre 
  
Outpatient 
Clinic level 
cost 
non-
governmental 
organisation 
level cost 
Total 
MT 
direct cost $1.62 $0.51 $2.13 
indirect cost $0.01 $1.28 $1.29 
total $1.63 $1.80 $3.42 
VCT 
direct cost $0.31 $0.18 $0.49 
indirect cost $0.00 $0.30 $0.30 
total $0.31 $0.48 $0.79 
MED 
direct cost $41.89 $24.50 $66.39 
indirect cost $0.25 $39.94 $40.20 
total $42.14 $64.45 $106.59 
LAB 
direct cost $13.48 $7.89 $21.37 
indirect cost $0.08 $12.86 $12.94 
total $13.56 $20.74 $34.31 
PHA 
direct cost $329.09 $192.50 $521.58 
indirect cost $1.99 $313.78 $315.77 
total $331.08 $506.28 $837.36 
HBC 
direct cost $20.43 $11.95 $32.39 
indirect cost $0.12 $19.48 $19.61 
total $20.56 $31.44 $52.00 
NUT 
direct cost $0.72 $0.42 $1.15 
indirect cost $0.00 $0.69 $0.69 
total $0.73 $1.11 $1.84 
ADH 
direct cost $3.52 $2.06 $5.59 
indirect cost $0.02 $3.36 $3.38 
total $3.55 $5.42 $8.97 
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 Cost of the most important medicines used in the programme 
  Cost per unit 
Item designation 
International 
price in 2008 
USD 
CIF price in 
2008 USD 
CIF+storage 
and transport 
in 2008 USD 
CIF price in 
2000 USD 
Cotrimoxazole 800/160mg $0.01 $0.013 $0.014 $0.011 
Cotrimoxazole 400/80mg $0.01 $0.013 $0.014 $0.011 
Cotrimoxazole Siro 40/200mg $1.00 $1.119 $1.169 $0.913 
Dapsol 100mg $0.01 $0.010 $0.011 $0.008 
Clindamycin 150mg $0.06 $0.069 $0.072 $0.057 
Azithromycine 250mg $0.19 $0.210 $0.219 $0.171 
Azithromycine bột 200mg $0.19 $0.210 $0.219 $0.171 
Metronidazole 250mg (klion) $0.14 $0.157 $0.164 $0.128 
Ciprofloxacine 500mg $0.04 $0.045 $0.047 $0.037 
Cephalexin 500mg $0.08 $0.094 $0.098 $0.077 
Amoxycilin 500mg $0.07 $0.075 $0.079 $0.062 
Cefuroxime acetyl 250mg $0.45 $0.503 $0.525 $0.410 
Doxycyclin 100mg $0.01 $0.012 $0.013 $0.010 
Ceftriaxone IV 250mg $4.30 $4.811 $5.026 $3.927 
Benzathine PenicillineIM 1.2 MUI $0.42 $0.475 $0.497 $0.388 
Fluconazole 150mg $0.59 $0.661 $0.690 $0.539 
Itrazonazole 100mg $0.71 $0.799 $0.835 $0.652 
Miconazole gel $0.73 $0.817 $0.854 $0.667 
Clotrimazole 100mg $0.14 $0.157 $0.164 $0.128 
Diflucan 200mg $0.39 $0.440 $0.460 $0.359 
Clotrimazole $0.14 $0.157 $0.164 $0.128 
Acyclovir 200mg $0.05 $0.057 $0.059 $0.046 
Mebendazole 100mg $0.03 $0.038 $0.040 $0.031 
Albedazole 200mg $1.36 $1.523 $1.591 $1.243 
Loperamid 2mg $0.01 $0.009 $0.009 $0.007 
Cimetidine 300mg $0.03 $0.031 $0.033 $0.026 
Simethicone 80mg $0.04 $0.044 $0.046 $0.036 
Loperamid 2mg $0.01 $0.009 $0.009 $0.007 
Metaclopramide 10mg $0.10 $0.112 $0.117 $0.091 
Acetaminophen 500mg $0.00 $0.004 $0.005 $0.004 
Acetaminophen/Codein 500mg/30mg $0.05 $0.051 $0.054 $0.042 
Acetaminophen 120mg/5ml  $1.31 $1.468 $1.534 $1.199 
Acetaminophen 160mg/5ml  $0.97 $1.084 $1.132 $0.885 
Ibuprofen 200mg $0.01 $0.008 $0.008 $0.007 
Ibuprofen siro 100mg/5ml $0.78 $0.874 $0.913 $0.713 
Prednisolone 5mg $0.00 $0.004 $0.005 $0.004 
Aspirin 500mg PH8 $0.01 $0.010 $0.010 $0.008 
Tylenol $1.12 $1.257 $1.313 $1.026 
Promethazine 15mg $0.01 $0.008 $0.008 $0.007 
Promethazine siro 0,1% $0.20 $0.220 $0.230 $0.180 
Multivitamin $0.00 $0.004 $0.004 $0.003 
Multivitamin siro $0.88 $0.986 $1.030 $0.805 
Vitamin 3B $0.01 $0.013 $0.014 $0.011 
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Vitamine C 500mg $0.04 $0.044 $0.046 $0.036 
Fe-Folic $0.03 $0.038 $0.039 $0.031 
Oxomemazine + Guaifenesin  $0.51 $0.574 $0.599 $0.468 
Acetylcystein 100mg $0.05 $0.053 $0.056 $0.044 
d4T/3TC/NVP $0.14 $0.155 $0.162 $0.127 
ZDV/3TC/NVP $0.33 $0.368 $0.384 $0.300 
d4T 30mg $0.03 $0.032 $0.034 $0.026 
d4T 40mg $0.07 $0.080 $0.084 $0.065 
ZDV 300mg $0.09 $0.099 $0.103 $0.080 
ZD4/3TC 300/150mg $0.19 $0.216 $0.225 $0.176 
3TC 150mg $0.05 $0.057 $0.059 $0.046 
NVP 200mg $0.06 $0.067 $0.070 $0.054 
EFV 600mg $0.40 $0.450 $0.470 $0.367 
DDI 200mg $0.12 $0.137 $0.143 $0.112 
DDI 100mg $0.14 $0.152 $0.159 $0.124 
DDI 25mg $0.12 $0.137 $0.143 $0.112 
ABC 300mg $0.47 $0.529 $0.553 $0.432 
NFV 250mg $0.64 $0.717 $0.749 $0.585 
TDF 300mg $0.48 $0.535 $0.559 $0.437 
LPV/r $0.48 $0.537 $0.561 $0.438 
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 Resume 
 
Experience 
General Director and Founder of Urban Care Ltd., Hanoi, Vietnam, April 2010 – Present   
Lead Consultant for AMI in Thailand: program performance, sustainability, ownership and cost 
analysis, November - December 2010 
General evaluation of Aide Medicale Internationale’s program in the Tak Province in the Karen refugees 
camps of Mae La, Nupoh and Umpiem, primary health care and general prevention services. 80,000 
refugees covered by the program 
Lead Consultant on cost and cost-effectiveness analysis for FHI Vietnam, Hanoi, Vietnam, 
October 2010 - March 2011 
Costs, unit-costs and cost-effectiveness analysis of FHI Vietnam’s HIV intervention portfolio in Vietnam 
covering outreach, counseling and testing, care & treatment, and community-based intervention. 25 sites 
and 70 program components 
Rapporteur for Family Health International Headquarters - Hanoi - August 2010 
Rapporteur for their internal world SPME - Strategic Information meeting. 
Country Medical Coordinator, Médecins du Monde France, Hanoi, Vietnam - Jan 2008 – Nov 2009   
Medical guidance at country level of the HIV program, M&E tools development & supervision, IEC & BCC 
materials development, donor technical relation, budget building and follow-up. 2000 People Living with 
HIV/AIDS registered, in 2 cities and 3 sites. 
Medical Coordinator, Médecins du Monde France, Hanoi, Vietnam - Jan 2007- Dec 2008  
Close technical management of the Tay Ho Outpatient Clinic: VCT, HBC, HAART and human resources, 
IEC & BCC materials development, OVC network development, and M&E systems implementation and 
supervision. 600 People Living with HIV/AIDS registered. 
Medical referent, Médecins du Monde France, Rabat, Morocco, Aug – Oct 2006  
Building and technical supervision of a PHC centre for illegal sub-saharian migrants in transition in Rabat: 
general medicine, reproductive health, TB and HIV. Target population of 5,000 
General Practitioner – Family Doctor, France, 2004 -2006  
Resident, Pediatric service of the university hospital of Yaoundé, Cameroon, March - Sept 2003 
Paediatric clinical care (malnutrition, lung-infections, malaria, HIV and TB). Research on the social, 
geographic and economic accessibility of the service. 
Tutor/teacher in biostatistics of pre-graduate medical students, Bordeaux, France, Access Ltd - 
1995 – 1998  
 
Education 
Ph.D in Epidemiology, Swiss Tropical and Public Health Institute, Basel, Switzerland - Oct 2007- 
Nov 2010   
On the cost-effectiveness evaluation of the prevention and care & treatment HIV site of Tay Ho, Hanoi. Unit-
costs, financial and economic analysis, DALY analysis, and affordability of the program. Under the direction 
of Pr M. Tanner. 
Medical Doctor degree, Bordeaux II Medical School, Bordeaux, France - 2004  
Thesis: Modeling the accessibility of the Yaounde’s university hospital pediatric service 
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Master of Science in International Health, Bordeaux II medical school and Troped network, 
France and Europe - 2002-2004  
(advanced modules at the Swiss Tropical Institute, the Heidelberg Institute of Tropical Medicine, and the 
London School of Tropical Hygiene) 
Degree in Tropical Medicine and Hygiene, Bordeaux II medical school, Bordeaux, France 2002
  
 
 
 
 
